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1 © European Food Safety Authority, 2012 
SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 21, Revision 3 
(FGE.21Rev3): 
Thiazoles, thiophenes, thiazoline and thienyl derivatives from chemical  
groups 29 and 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 59 flavouring substances in the Flavouring Group 
Evaluation 21, including an additional three substances in this Revision 3, using the Procedure in 
Commission Regulation (EC) No 1565/2000. Since the publication of the last revision of this FGE, the 
EFSA has been requested to evaluate three additional substances [FL-no: 15.057, 15.079 and 15.135], 
which have been included in the present revision of FGE.21. Seven of the substances [FL-no: 15.060, 
15.086, 15.090, 15.099, 15.114, 15.119 and 15.133] were considered to have genotoxic potential. The 
remaining 52 substances were evaluated through a stepwise approach (the Procedure) that integrates 
information on structure-activity relationships, intake from current uses, toxicological threshold of 
concern, and available data on metabolism and toxicity. The Panel concluded that 26 substances [FL-
no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 
15.069, 15.071, 15.078, 15.080, 15.082, 15.084, 15.085, 15.087, 15.089, 15.098, 15.108, 15.115, 
15.116 and 15.118] do not give rise to safety concerns at their levels of dietary intake, estimated on the 
basis of the MSDI approach. For the remaining 26 candidate substances [FL-no: 15.037, 15.040, 
15.042, 15.043, 15.045, 15.054, 15.055, 15.057, 15.064, 15.070, 15.072, 15.074, 15.076, 15.077, 
15.079, 15.088, 15.091, 15.092, 15.093, 15.094, 15.096, 15.097, 15.106, 15.107, 15.129 and 15.135] 
evaluated through the Procedure, no appropriate NOAEL was available and additional data are 
required. Besides the safety assessment of these flavouring substances, the specifications for the 
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materials of commerce have also been considered. For one substance [FL-no: 15.129], evaluated using 
the Procedure, an identity test is lacking and for four substances [FL-no: 15.042, 15.057, 15.079 and 
15.135] the stereoisomeric composition has not been specified sufficiently. 
© European Food Safety Authority, 2011 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate 59 flavouring substances in the 
Flavouring Group Evaluation 21, Revision 3 (FGE.21Rev3), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 59 flavouring substances belong to chemical 
group 29 and 30, Annex I of the Commission Regulation (EC) No 1565/2000.  
The FGE.21Rev3 includes the assessment of three additional substances [FL-no: 15.057, 15.079 and 
15.135] compared to the previous revision of FGE.21. 
In the present FGE.21Rev3, the 59 flavouring substances include five- and six-membered sulphur-
containing aromatic and non-aromatic heterocycles, which have been arranged into 11 subgroups in 
order to facilitate comparisons of the data sets between the groups. This division was done on the basis 
of degree of aromaticity and according to the presence of other heteroatoms (i.e. nitrogen).  
Twelve flavouring substances possess one or more chiral centres. For four of these substances [FL-no: 
15.042, 15.057, 15.079 and 15.135] the stereoisomeric composition has not been specified sufficiently. 
Forty-six of the flavouring substances are classified into structural class II and 13 candidate substances 
are classified into structural class III, according to the decision tree approach presented by Cramer et 
al., 1978. 
Forty-four candidate substances in the present group have been reported to occur in a wide range of 
food items.  
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the flavouring substances in this group have intakes in 
Europe from 0.0012 to 5.7 microgram/capita/day, which are below the thresholds of concern for 
structural class II (540 microgram/person/day) and structural class III (90 microgram/person/day). 
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On the basis of the reported annual production volumes in Europe, the combined estimated daily per 
capita intakes as flavourings of the substances in subgroups with more than one substance from a 
structural class range from 0.14 to 8.0 microgram. For none of the subgroups do the total combined 
intakes exceed the thresholds of concern for compounds belonging to structural class II of 540 
microgram/person/day or to structural class III of 90 microgram/person/day. 
The genotoxicity data for the flavouring substances in FGE.21Rev3 are limited and genotoxicity could 
not be assessed adequately. However, except for two dihydrothiazines, 6-acetyl-2,3-dihydro-1,4-
thiazine [FL-no: 15.114] (Register name: 5-acetyl-2,3-dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-
1,4-thiazine [FL-no: 15.133], two thiazolidines, 2-methylthiazolidine [FL-no: 15.090] and 2-
propylthiazolidine [FL-no: 15.099] and three structurally related thiazolines, 2-methyl-2-thiazoline 
[FL-no: 15.086], 2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 
15.119], the genotoxicity data available do not preclude the evaluation of the remaining 52 candidate 
substances using the Procedure. 
None of the 52 flavouring substances evaluated through the Procedure can be predicted to be 
metabolised to innocuous products. 
Toxicological data on flavouring substances as well as data on structurally related substances were 
limited. Valid toxicological data which could provide an adequate margin of safety compared to the 
intakes from use as flavouring substances were only available for the 26 candidate substances from 
subgroup A-Ic (thiophenes with thiol-containing ring substituents) and subgroup A-II (thiazoles). For 
the remaining 26 candidate substances belonging to the subgroups of thiophene itself (A-Ia), 
thiophenes with non-thiol-containing ring substituents (A-Ib), benzothiazoles (A-III), 
dihydrothiophenes (B-I), dithiazines (B-IV) and thiadiazines (B-VI), the Panel concluded that there 
were insufficient data available to provide margins of safety from their use as flavouring substances 
and that additional toxicity data are needed. 
The Panel concluded that 26 of the flavouring substances evaluated through the Procedure [FL-no: 
15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 
15.069, 15.071, 15.078, 15.080, 15.082, 15.084, 15.085, 15.087, 15.089, 15.098, 15.108, 15.115, 
15.116 and 15.118] are not of safety concern at their estimated levels of intake based on the MSDI 
approach, whereas for 26 candidate substances [FL-no: 15.037, 15.040, 15.042, 15.043, 15.045, 
15.054, 15.055, 15.057, 15.064, 15.070, 15.072, 15.074, 15.076, 15.077, 15.079, 15.088, 15.091, 
15.092, 15.093, 15.094, 15.096, 15.097, 15.106, 15.107, 15.129 and 15.135], additional toxicological 
data are required. 
The estimated intakes, based on the mTAMDI, for the 41 flavouring substances assigned to structural 
class II and evaluated using the Procedure, range from 78 to 4000 microgram/person/day. For one of 
these substances [FL-no: 15.129] the mTAMDI value of 4000 microgram/person/day is above the 
threshold of concern of 540 microgram/person/day for structural class II. The estimated intakes, based 
on the mTAMDI, for nine of the 11 candidate substances assigned to structural class III and evaluated 
through the Procedure, range from 78 to 250 microgram/person/day. For four of these nine substances 
[FL-no: 15.042, 15.055, 15.088 and 15.135] the estimated intakes are above the threshold of concern 
for structural class III substances of 90 microgram/person/day. For two substances [FL-no: 15.057 and 
15.079] no use levels were provided. Therefore, more reliable exposure data are required for [FL-no: 
15.042, 15.055, 15.057, 15.079, 15.088, 15.129 and 15.135]. On the basis of such additional data, 
these flavouring substances should be re-evaluated using the Procedure. 
In order to determine whether the conclusion for the 52 candidate substances which have been 
evaluated using the Procedure can be applied to the materials of commerce, it is necessary to consider 
the available specifications. Adequate specifications including purity and identity for the materials of 
commerce have been provided for 47 flavouring substances evaluated through the Procedure. An 
identity test has not been provided for one substance [FL-no: 15.129] and for [FL-no: 15.042, 15.057, 
15.079 and 15.135] the stereoisomeric composition has not been specified sufficiently. 
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Thus, the final evaluation of the materials of commerce cannot be performed for five substances [FL-
no: 15.042, 15.057, 15.079, 15.129 and 15.135] evaluated through the Procedure, pending further 
information on stereoisomerism and an identity test (for [FL-no: 15.129]).  
For 26 flavouring substances evaluated through the Procedure [FL-no: 15.037, 15.040, 15.042, 15.043, 
15.045, 15.054, 15.055, 15.057, 15.064, 15.070, 15.072, 15.074, 15.076, 15.077, 15.079, 15.088, 
15.091, 15.092, 15.093, 15.094, 15.096, 15.097, 15.106, 15.107 15.129 and 15.135] the Panel 
considered that additional toxicity data are needed. Furthermore, for seven substances [FL-no: 15.060, 
15.086, 15.090, 15.099, 15.114, 15.119 and 15.133] the Panel concluded that genotoxicity data are 
required. 
For the remaining 26 flavouring substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 
15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.080, 15.082, 15.084, 
15.085, 15.087, 15.089, 15.098, 15.108, 15.115, 15.116 and 15.118] evaluated using the Procedure, 
the Panel concluded that they would present no safety concern at their estimated levels of intake based 
on the MSDI approach. 
KEYWORDS 
Flavourings, safety, thiophene, thiophene derivatives, dihydrothiophene, benzothiazole derivatives 
thiazole derivatives, thiazoline derivatives, thiazolidine derivatives, dihydrothiazine derivatives, 
dithiazine derivatives, FGE.21. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
In FGE.21 and FGE.21Rev1, the Panel considered that additional toxicity data were needed for 23 of 
the substances (Subgroups A-Ia, A-Ib, A-III, B-I, B-IV and B-VI) evaluated through the Procedure, as 
no adequate toxicity study from which a no observed adverse effect level (NOAEL) could be 
established was available, neither on the candidate substances nor on supporting substances. Although 
additional toxicity data and metabolism data have become available for two substances, [FL-no: 
15.106] from subgroup A-Ia and [FL-no: 15.096] from subgroup A-Ib (Flavour Industry, 2010b), in 
FGE.21Rev2, the Panel concluded that the data were not valid for the purposes of establishing a 
NOAEL. 
In FGE.21Rev2, information on stereoisomeric composition provided by EFFA on nine substances 
[FL-no: 15.042, 15.054, 15.055, 15.060, 15.077, 15.090, 15.099, 15.119 and 15.129] (EFFA, 2010a) 
and followed by additional information on [FL-no: 15.054, 15.119 and 15.129] (EFFA, 2011f) was 
included. 
Industry has informed that 11 substances [FL-no: 15.037, 15.042, 15.077, 15.088, 15.090, 15.094, 
15.099, 15.107, 15.114, 15.129 and 15.133] are no longer supported for use as flavouring substances 
in Europe (EFFA, 2009c).  
FGE Opinion adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.21 8 February 2007 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178694698331.htm 
54 
FGE.21Rev1 26 March 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1023.htm 56 
FGE.21Rev2 4 February 2011 http://www.efsa.europa.eu/en/efsajournal/doc/1989.pdf 56 
FGE.21Rev3 23 November 2011  59 
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The present revision of FGE.21, FGE.21Rev3, includes the assessment of three additional substances, 
4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135]. 
No toxicity or metabolism data were provided for these substances. A search in the open literature did 
not reveal any further data on toxicity or metabolism for these substances. 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), prior to their authorisation and inclusion in the Union list 
(Regulation (EC) No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
After the finalisation of the evaluation programme, in their letter of the 12th April 2010, the 
Commission requested EFSA to carry out an evaluation of ethyl thialdine [FL-no: 15.135], also 
according to Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission 
has asked EFSA to reflect newly requested information on specifications in the revisions of FGEs. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 21 Revision 3 
1.1. Description 
The present Flavouring Group Evaluation 21, Revision 3 (FGE.21Rev3), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a), (The Procedure –shown in 
schematic form in Annex I of this FGE), deals with 59 flavouring substances (candidate substances) 
from chemical groups 29 and 30, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 
2000a). The candidate substances in FGE.21Rev3 fall into the chemical groups of thiazoles (S- and N-
containing), thiazolines (S- and N- containing), thienyl derivatives (S-containing), thiophenes and 
thiophene itself (S-containing) (see Table 4.1 in Section 4). 
The candidate substances as well as their chemical Register names, FLAVIS- (FL-no), Chemical 
Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufacturers 
Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
A summary of the outcome of the safety evaluation of the candidate substances are listed in Table 2. 
The candidate substances are structurally closely related to 29 flavouring substances (supporting 
substances) evaluated at the 59th JECFA meeting (JECFA, 2002c) in the group of “Sulphur–containing 
heterocyclic compounds”. Two of these supporting substances are mixtures (one of two isomeric 
isobutyl-substituted (JECFA-no: 1046) and one of two isomeric isopropyl-substituted 
dimethyldihydrodithiazine (JECFA-no: 1047) derivatives) and not included in the Register (see Table 
3).  
1.2. Stereoisomers  
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different; they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
FGE.21Rev3
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provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
Five of the candidate substances possess one chiral centre [FL-no: 15.060, 15.077, 15.090, 15.099 and 
15.119], three substances possess two chiral centres [FL-no: 15.054, 15.129 and 15.135] and four 
possess three chiral centres [FL-no: 15.042, 15.055, 15.057 and 15.079]. For four of these substances 
[FL-no: 15.042, 15.057, 15.079 and 15.135] the stereoisomeric composition has not been specified 
sufficiently. The Flavour Industry has informed that [FL-no: 15.042] is a “mixture of 
diastereoisomers” (EFFA, 2010a),  however, the actual ratio has to be given (see Table 1). 
1.3. Natural Occurrence in Food 
Forty–four candidate substances have been reported to occur naturally in one or more of the following 
food items: shellfish, shrimps, squid, pork, beef, lamb, chicken, vegetables, peanut, wheaten bread, 
butter, cheese, tea, coffee, cocoa and various types of alcoholic beverages. Quantitative data on the 
natural occurrence in foods have been reported for 14 of these substances (TNO, 2000; TNO, 2010; 
TNO, 2011), see Table 1.3.1. 
1.3.1 Candidate substances reported to occur in food (TNO, 2000; TNO, 2011) 
FL-no: Name: Quantitative data reported 
15.038 2-Acetyl-4-methylthiazole 0.02 mg/kg in kohlrabi 
15.040 2-Acetylthiophene Up to 1.25 mg/kg in coffee, 0.02 mg/kg in kohlrabi,  up to 0.00002 mg/kg in pork (grilled, roasted) 
15.061 2,5-Dimethyl-4-ethylthiazole 0.00001 mg/kg in pork (grilled, roasted) 
15.062 2,4-Dimethylthiazole Up to 0.00004 mg/kg in pork (grilled, roasted) 
15.064 2,5-Dimethylthiophene Up to 0.01 mg/kg in papaya, up to 0.0007 mg/kg in whisky 
15.069 4-Ethyl-5-methylthiazole Up to 0.00001 mg/kg in pork (grilled, roasted) 
15.076 2-Hexylthiophene Up to 0.002 mg/kg in guinea hen 
15.091 2-Methylthiophene 
Up to 0.0076 mg/kg in beef (grilled, roasted), trace amounts in chicken (roasted), up 
to 0.1 mg/kg in papaya, 0.0009 mg/kg in shrimps (cooked), up to 0.0073 mg/kg in 
whisky 
15.092 3-Methylthiophene Up to 0.01 mg/kg in papaya 
15.096 2-Pentylthiophene 0.001 mg/kg in chicken (roasted) 
15.097 2-Propionylthiophene 0.8 mg/kg in coffee 
15.106 Thiophene 0.0005 mg/kg in chicken (roasted), up to 0.8 mg/kg in tea, up to 0.0032 mg/kg in whisky 
15.107 Thiophene-2-carbaldehyde 0.01 mg/kg in asparagus (cooked), 0.4 mg/kg in camembert, up to 1.8 mg/kg in coffee, up to 0.04 mg/kg in grape brandy, up to 0.03 mg/kg in malt whisky 
15.135 Ethyl thialdine 0.02 mg/kg in krill, up to 0.3 mg/kg in shrimps 
 
Fifteen of the candidate substances have not been reported to occur naturally in any food items 
according to TNO (TNO, 2000; TNO, 2010; TNO, 2011), see Table 1.3.2. 
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1.3.2 Candidate substances not reported to occur in food (TNO, 2000; TNO, 2010; TNO, 2011) 
FL-no: Name: 
15.042 2-Butyl-4-methyl(4H)pyrrolidino-[1,2d]-1,3,5-dithiazine 
15.044 2-Butylthiazole 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 
15.074 5-Ethylthiophene-2-carbaldehyde 
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 
15.082 3-Mercaptothiophene 
15.087 2-Methyl-3-mercaptothiophene 
15.108 2-Thiophenemethanethiol 
15.114 6-Acetyl-2,3-dihydro-1,4-thiazine (Register name: 5-acetyl-2,3-dihydro-1,4-thiazine) 
15.115 2-Isobutyl-4-methylthiazole 
15.116 2-Acetyl-4-ethylthiazole 
15.119 2-Isobutyl-3-thiazoline 
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine 
2. Specifications 
Purity criteria for the candidate substances have been provided by the flavouring industry (EFFA, 
2004i; EFFA, 2011e; Flavour Industry, 2010j). Judged against the requirements in Annex II of 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), the information is adequate for 57 
substances. For two substances [FL-no: 15.129 and 15.133] an identity test is missing. Furthermore for 
four candidate substances [FL-no: 15.042, 15.057, 15.079 and 15.135], the stereoisomeric composition 
has not been specified sufficiently (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
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One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g. it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The total annual volume of production of the candidate substances from use as flavouring substances 
in Europe has been reported to be approximately 130 kg (EFFA, 2004f; EFFA, 2011e; Flavour 
Industry, 2010j). 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-
isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 15.079] and 2-acetylthiophene [FL-no: 15.040] 
accounts for 80 kg. For 23 of the 29 supporting substances the annual volume of production is 
approximately 4200 kg in Europe (JECFA, 2003a). Thiamine hydrochloride [FL-no: 16.027] accounts 
for 2500 kg and 5-(2-hydroxyethyl)-4-methylthiazole [FL-no: 15.014] for 1200kg. There was no 
reported production in Europe for five of the supporting substances in the Register [FL-no: 15.005, 
15.029, 15.030, 15.109 and 15.113] and for one of the non-Register supporting substances. 
On the basis of the annual volumes of production reported for the candidate substances, the daily per 
capita intakes for each of these flavourings have been estimated (Table 2).  
The estimated daily per capita intake of 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 
15.079], from use as a flavouring substance is 5.7 microgram, of 2-acetylthiophene [FL-no: 15.040] 
2.2 microgram, of 4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057] 1.5 
microgram and of 4-butylthiazole [FL-no: 15.118] 1.3 microgram. For the remaining 55 substances, 
the estimated daily per capita intakes are in the range of 0.0012 to 0.61 microgram (see Table 2). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995).  
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is consistent 
(comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for the enlarged EU. 
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For the present evaluation of the candidate substances, information on food categories and normal and 
maximum use levels5,6,7 were submitted by the Flavour Industry (EFFA, 2004g; EFFA, 2004i; EFFA, 
2007a; Flavour Industry, 2004-5; Flavour Industry, 2010j) for 57 substances. No information on use 
levels have been submitted for [FL-no: 15.057 and 15.079]. The candidate substances are used in 
flavoured food products divided into the food categories outlined in Annex III of the Commission 
Regulation (EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the present calculation of the 
mTAMDI, the reported normal use levels were used. In the case where different use levels were 
reported for different food categories the highest reported normal use level was used. 
Table 3.1 Use of Candidate Substances in various food categories for 57 candidate substances for which 
data on use have been provided. 
Food 
category 
Description Flavourings used* 
01.0 Dairy products, excluding products of category 2 All 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 15.094 
and 15.135] 
04.1 Processed fruits All 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and 
nuts & seeds 
[FL-no: 15.062, 
15.129,15.133 and 15.135] 
05.0 Confectionery All except [FL-no: 15.062 
and 15.135] 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
All 
07.0 Bakery wares All 
08.0 Meat and meat products, including poultry and game All 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-no: 15.039 
and 15.135] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 15.089] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 15.129, 
15.133 and 15.135] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All except [FL-no: 15.135] 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All except [FL-no: 15.062 
and 15.135] 
15.0 Ready-to-eat savouries All except [FL-no: 15.068] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed 
in categories 1 – 15 
All except [FL-no: 15.135] 
* No use levels have been submitted for [FL-no: 15.057 and 15.079] 
According to the Flavour Industry the normal use levels are in the range of 0.1-10 mg/kg food, and the 
maximum use levels are in the range of 0.2-250 mg/kg (EFFA, 2004g; EFFA, 2004i; EFFA, 2007a; 
Flavour Industry, 2004-5; Flavour Industry, 2010j).  
The mTAMDI values for the 46 candidate substances from structural class II (see Section 5) range 
from 78 to 4000 microgram/person/day. For the remaining 11 candidate substances from structural 
class III for which data have been provided, the mTAMDI range from 78 to 4000 
microgram/person/day. 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported usages (EFFA, 
2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived from 12 model 
flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 “Alcoholic beverages” for 
substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
The 59 candidate substances are structurally related to 29 supporting substances evaluated by the 
JECFA in “Sulfur-containing heterocyclic compounds” (JECFA, 2003a). The substances are divided 
into 11 subgroups based on the nature of the ring (aromatic (clustered in subgroups A-Ia,-b,-c, A-II 
and A-III) vs. non-aromatic (clustered in subgroups B-I to B-VI)) depending on type and number of 
ring heteroatoms (sulphur or sulphur with nitrogen), and the degree of saturation in the non-aromatic 
rings. The assignment of the individual substances to the different subgroups is presented in Table 4.1. 
The structures of the substances and a description of the characteristic features of the 11 subgroups are 
also given in Table III.1 and the accompanying text in Annex III. 
TABLE 4.1 DIVISION OF CANDIDATE SUBSTANCES INTO STRUCTURAL SUBGROUPS 
Subgroup and common ring structure Register name FL-no 
A Aromatic subgroups 
A-Ia: Thiophene 
S
 
Thiophene 15.106 
A-Ib: Thiophenes: (with non-thiol-containing ring 
substituents) 
S
R  
2-Methylthiophene 15.091 
3-Methylthiophene 15.092 
2-Ethylthiophene 15.072 
2-Butylthiophene 15.045 
2-Pentylthiophene (Register name: sec-Pentylthiophene)  15.096 
2-Hexylthiophene 15.076 
2-Octylthiophene 15.093 
2,5-Dimethylthiophene 15.064 
2-Ethyl-5-methylthiophene 15.070 
2-Butyl-5-ethylthiophene 15.043 
2-Acetylthiophene 15.040 
2-Propionylthiophene 15.097 
2-Pentanoylthiophene 15.094 
2-Acetyl-3-methylthiophene 15.037 
Thiophene-2-carbaldehyde 15.107 
5-Ethylthiophene-2-carbaldehyde 15.074 
A-Ic: Thiophenes: (with thiol-containing ring 
substituents) 
S
(R)-SH
 
3-Mercaptothiophene 15.082 
2-Thiophenemethanethiol 15.108 
2-Methyl-3-mercaptothiophene 15.087 
A-II: Thiazoles 
2-Methylthiazole 15.089 
2-Ethylthiazole 15.071 
2-Propylthiazole 15.098 
2-Butylthiazole 15.044 
4-Butylthiazole 15.118 
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TABLE 4.1 DIVISION OF CANDIDATE SUBSTANCES INTO STRUCTURAL SUBGROUPS 
Subgroup and common ring structure Register name FL-no 
S
N  
2,4-Dimethylthiazole 15.062 
2,5-Dimethylthiazole 15.063 
5-Ethyl-2-methylthiazole 15.068 
4-Ethyl-2-methylthiazole 15.067 
4-Ethyl-5-methylthiazole 15.069 
2,5-Diethylthiazole 15.052 
5-Methyl-2-pentylthiazole 15.084 
4,5-Dimethyl-2-ethylthiazole 15.058 
2,5-Dimethyl-4-ethylthiazole 15.061 
2,5-Diethyl-4-methylthiazole 15.050 
2,5-Diethyl-4-propylthiazole 15.051 
2-Isobutyl-4-methylthiazole 15.115 
2-Isobutyl-4,5-dimethylthiazole 15.078 
2-Isopropyl-4,5-dimethylthiazole 15.080 
2-Acetyl-4-methylthiazole 15.038 
2-Acetyl-5-methylthiazole 15.039 
2-Acetyl-4-ethylthiazole 15.116 
4-Methyl-2-propionylthiazole 15.085 
A-III: Benzothiazoles 
S
N  
2-Methyl-4,5-benzothiazole 15.088 
B Non-aromatic subgroups: 
B-I : Dihydrothiophenes 
S
 
4-Hydroxy-2,5-dimethylthiophen-3(2H)-one 15.077 
B-II: Thiazolines 
S
N  
2-Methyl-2-thiazoline 15.086 
2,4-Dimethyl-3-thiazoline 15.060 
2-Isobutyl-3-thiazoline 15.119 
B-III: Thiazolidines 
S
N
H  
2-Methylthiazolidine 15.090 
2-Propylthiazolidine 15.099 
B-IV: Dithiazines 
Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 15.054 
2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 15.055 
2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine 15.042 
4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine 15.057 
2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 15.079 
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TABLE 4.1 DIVISION OF CANDIDATE SUBSTANCES INTO STRUCTURAL SUBGROUPS 
Subgroup and common ring structure Register name FL-no 
NH
S
S
 
Ethyl thialdine 15.135 
  
B-V: Dihydrothiazines 
S
N
H  
6-Acetyl-2,3-dihydro-1,4-thiazine (Register name: 5-acetyl-
2,3-dihydro-1,4-thiazine) 
15.114 
5-Acetyl-2,3-dihydro-1,4-thiazine 15.133 
B-VI: Thiadiazine 
HN NH
S
 
Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 15.129 
From the few data available on absorption, distribution and elimination of the aromatic candidate 
substances in this FGE, it is anticipated that they may be absorbed and eliminated after 
biotransformation. Some volatile substances may also be eliminated unchanged via exhalation. For the 
non-aromatic substances there are no data available for the candidate or for the supporting substances. 
For the evaluation of the metabolism of the candidate substances, only limited data were available. 
These were confined to a few studies on thiophene, and some thiophene-, thiazole- and benzothiazole-
derivatives (i.e. only directly relevant for the evaluation of subgroups-A (A-Ia, -Ib, -Ic, -II, -III)), the 
aromatic candidate substances. Other information was found in several review papers. However, 
virtually no data were found on the metabolism of substances from the B-subgroups (B-I, -II, -III, -IV, 
-V, -VI) possessing non-aromatic ring structures. 
Metabolism of substances in subgroup A-I 
Thiophene and the ring-substituted thiophenes (A-Ia, b and c) may undergo S-oxidation to give 
sulphoxides. These primary metabolites may react spontaneously or via glutathione transferase with 
glutathione (GSH), and it is likely that they also exhibit reactivity towards protein thiols. The 
glutathione conjugates may be further metabolised to the corresponding mercapturic acids and 
excreted in the urine. S-oxide intermediates may also be subject to dimerisation via a Diels-Alder 
reaction. In addition, 4,5-epoxide formation has been reported for 2-phenylthiophene, followed by 
subsequent conjugation of the epoxide with glutathione. This may also be anticipated for other ring-
substituted thiophenes. 
Only very limited information was submitted to show whether side chain oxidation of the ring-
substituted thiophenes could also occur. Based on some studies with a substituted thiazole 
(chlormethiazole) and one (heavily) substituted thiophene (olanzapine), such side chain reactions may 
be anticipated. For the substances in subgroup A-Ib, metabolites of the side chain oxidation pathways 
may be expected to be conjugated, e.g. with glucuronic acid. Similar reactions (e.g. omega or omega-1 
oxidations) for ring-substituent chains have been discussed for alkylated pyrazines (EFSA, 2010h). 
The two thiophene carbaldehyde candidate substances [FL-no: 15.107 and 15.074] may be expected to 
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be oxidised to the corresponding carboxylic acids. Where applicable, conjugation with amino acids 
(e.g. glycine) or glucuronic acid may also be expected to occur (see FGE.13Rev2 (EFSA, 2011h); 
FGE.14Rev1 (EFSA, 2009f); FGE.17Rev2 (EFSA, 2010h)). The acyl-substituted thiophenes [FL-no: 
15.037, 15.040, 15.094 and 15.097] may be subject to keto-reduction, possibly followed by 
conjugation, similar to acetyl derivatives of furans (EFSA, 2011h) and of pyrazines (EFSA, 2010h). 
The mercapto-group in the ring-substituent of the substances in subgroup A-Ic may undergo S-
methylation to produce the corresponding methyl thioether, with further oxidation to the 
corresponding sulphoxide and sulphone. They may also react with glutathione or other endogenous 
thiol substances to form mixed disulphides, which may undergo reduction to thiols or oxidative 
desulphuration. Alternatively, they may undergo enzymatic oxygenation resulting in the formation of 
the corresponding sulphinic or sulphonic acids. These metabolites are all expected to be excreted in 
the urine. A more detailed discussion on the metabolism of sulphur compounds can be found in 
FGE.13Rev2 (EFSA, 2011h). 
Metabolism of substances in subgroup A-II 
Thiazoles may be subject to ring S- and N-oxidation. From the various studies with thiazole 
derivatives (A-II), it can be seen that their metabolites may react spontaneously with glutathione, and 
it is likely that they also exhibit reactivity towards biomacromolecules. In addition, for some thiazole 
derivatives, ring C-oxidation may be accompanied by heterocyclic ring cleavage which can result in 
the formation of alpha-diketone and thioamide intermediates. For the latter a relationship with nephro- 
and hepatotoxicity has been established, especially after GSH depletion, but this is a high-dose 
phenomenon. Due to the compound specificity of these reactions, the extent of formation cannot be 
generalised, however, these thioamide intermediates and the S-oxides seem to be quantitatively minor 
metabolites. 
Similarly to the situation with the ring-substituted thiophenes, only very limited information was 
available which could demonstrate whether side chain oxidation of the ring-substituted thiazoles could 
occur. Based on some studies with a substituted thiazole (chlormethiazole) such side chain reactions 
may be anticipated. Metabolites of the side chain oxidation pathways may be expected to be 
conjugated, e.g. with glucuronic acid. Similar reactions (e.g. omega or omega-1 oxidations) for ring-
substituent chains have been discussed for alkylated pyrazines (EFSA, 2010h). The acyl-substituted 
thiazoles [FL-no: 15.038, 15.039, 15.085 and 15.116] may be subject to keto-reduction, possibly 
followed by conjugation, similarly to acetyl derivatives of furanes (EFSA, 2011h) and pyrazines 
(EFSA, 2010h). 
Metabolism of substances in subgroup A-III 
In addition to ring cleavage as mentioned for the thiazoles in subgroup A-II, oxidation of the fused 
benzene ring has also been reported for some structural analogues of the candidate substance in 
subgroup A-III, 2-methyl-4,5-benzothiazole, [FL-no: 15.088]. No further information was available on 
the metabolism of this substance or on structurally related substances. 
Conclusions for the substances in the subgroups A-I to A-III 
From the very limited data available on the aromatic subgroups (A) it is not anticipated that the 
thiophenes (A-I) and thiazoles (A-II) utilise similar metabolic pathways. These sulphur-containing 
heteroaromatic derivatives can be expected to participate in metabolic pathways principally involving 
side-chain C-oxidation, epoxidation of double bonds, oxidation of the ring-S and (for the thiazoles) 
ring-N to yield sulphoxide or sulphones and N-oxides, respectively. The reactive intermediates (e.g. 
epoxides and S-oxides) may be conjugated with glutathione; the glutathione conjugates may be 
excreted directly in the urine or following further biotransformation to the corresponding mercapturic 
acids. Furthermore, from the data available it is anticipated that the unsubstituted thiophene (A-Ia) and 
benzothiazole (A-III) are metabolised differently from their ring-substituted derivatives. 
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In the light of the above considerations and as a consequence of the expected reactivity of the thiol 
groups and the possible reactions of the ring side-chains it cannot be anticipated that the substances in 
the aromatic subgroups (A) are metabolised to innocuous substances. The Panel was aware of the 
potential bio-activation of candidate substances with heteroaromatic rings to yield intermediates via 
ring-scission or S/N-oxidation which could be reactive to proteins or DNA. However, taking into 
account available data on structurally related thiazoles and considering the available genotoxicity data 
on thiophenes and thiazoles in the present revision of FGE.21 (FGE.21Rev3) (negative Ames tests and 
a chromosome aberration test), the Panel concluded that there are not sufficient indications to preclude 
the application of the Procedure to the thiophenes, thiazoles and benzothiazole (A-I to A-III). 
Metabolism of the substances in subgroups B-I to B-VI 
No specific information was available on the metabolism of the dihydrothiophene-, thiazoline-, 
thiazolidine-, dithiazine-, dihydrothiazine-, thiadiazine-derivatives or related substances for any of 
these non-aromatic substances in the B-subgroups. It may be speculated that the substances in these 
groups are metabolised primarily by oxidation of the ring-S, or, if applicable, via N-oxidation. In 
addition, metabolism of the ring substituents is likely to occur. 
The substances exhibiting thioacetal structures could be subject to acid hydrolysis in the stomach, 
similar to oxygen-containing acetals. However, thioacetals are more resistant than oxygen acetals. It is 
thus to be anticipated that these substances may reach the intestinal lumen intact and may also be 
absorbed as such. 
Conclusions for the substances in the subgroups B-I to B-VI 
Due to the lack of metabolism data it cannot be concluded that the candidate substances in the B-
subgroups will be metabolised to innocuous products. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances  
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the two candidate substance 6-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.114] (Register name: 5-
acetyl-2,3-dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.133] from subgroup 
B-V, which are alpha,beta-unsaturated ketones, i.e. they have a structural alert for genotoxicity 
(EFSA, 2008b), there are no genotoxicity data available and accordingly a concern for genotoxicity 
could not be ruled out. For the two candidate substances 2-methylthiazolidine [FL-no: 15.090] and 2-
propylthiazolidine [FL-no: 15.099] from subgroup B-III, there are indications of a genotoxic potentials 
in vitro. Considering the structural similarities between these two thiazolidines in subgroup B-III and 
the three thiazolines in subgroup B-II (2-methyl-2-thiazoline [FL-no: 15.086], 2,4-dimethyl-3-
thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119]), the Panel concluded that in 
the absence of further genotoxicity data the Procedure could not be applied to these five substances 
from subgroup B-II and B-III. 
Thus, the Panel concluded that in the absence of further genotoxicity data the Procedure could not be 
applied to the seven substances [FL-no: 15.060, 15.086, 15.090, 15.099, 15.114, 15.119 and 15.133]. 
For the safety evaluation of the remaining 52 candidate substances from chemical groups 29 and 30 
the Procedure as outlined in Annex I was applied, based on the MSDI approach. The outcome of the 
evaluations of the 52 substances are summarised in Table 2. 
Step 1 
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According to the decision tree approach, presented by Cramer et al. (Cramer et al., 1978) 41 of the 
candidate substances, evaluated through the Procedure, are classified into structural class II and 11 
into structural class III, see Table 2. 
Step 2 
None of the 52 candidate substances can be predicted to be metabolised to innocuous products. 
Therefore, the evaluation of all 52 candidate substances proceeds via the B-side of the Procedure. 
Step B3 
The 41 candidate substances in structural class II have estimated European daily per capita intakes 
(MSDI) ranging from 0.0012 microgram to 2.2 microgram (Tables 2 and 6.1). These intakes are below 
the threshold of concern of 540 microgram/person/day for structural class II substances.  
Similarly, the estimated daily per capita intakes of all 11 candidate substances in structural class III, 
ranging from 0.0012 microgram to 5.7 microgram (Tables 2 and 6.1), are below the threshold of 
concern for structural class III substances of 90 microgram/person/day.  
Accordingly, the evaluation of all 52 candidate substances proceeds to step B4. 
Step B4 
Subgroup A-Ia: Thiophene  
In the initial assessments of this flavouring group (FGE.21 (EFSA, 2008s), FGE.21Rev1 (EFSA, 
2009u) and FGE.21Rev2 (EFSA, 2011af), no valid toxicity study from which a No Observed Adverse 
Effect Level (NOAEL) could be established was available for the candidate substance or for any 
relevant supporting substance. Accordingly, further data were required for thiophene [FL-no: 15.106]. 
Although additional toxicity data were provided by Industry on thiophene (Flavour Industry, 2010b), 
the Panel considered that these data were not valid for the purposes of establishing a NOAEL to be 
used in the Procedure. Accordingly further data are still required for thiophene. 
Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents 
In the initial assessments of this flavouring group (FGE 21 (EFSA, 2008s) and FGE 21Rev1 (EFSA, 
2009u) and FGE.21Rev2 (EFSA, 2011af), no valid toxicity study from which a NOAEL could be 
established was available for the candidate substances or for any relevant supporting substances. 
Therefore, the Panel concluded that additional toxicity data are needed for the 16 substituted 
thiophenes in subgroup A-Ib. Although additional toxicity data were provided by Industry on the 
candidate substance 2-pentylthiophene (Register name: sec-pentylthiophene) [FL-no: 15.096] (Flavour 
Industry, 2010b), the Panel considered that these data were not valid for the purposes of establishing a 
relevant NOAEL for the subgroup. Accordingly additional toxicity data are still needed for the 16 
substituted thiophenes [FL-no: 15.037, 15.040, 15.043, 15.045, 15.064, 15.070, 15.072, 15.074, 
15.076, 15.091, 15.092, 15.093, 15.094, 15.096, 15.097 and 15.107] in subgroup A-Ib. 
Subgroup A-Ic: Thiophenes with thiol-containing ring substituents 
A NOAEL of 0.29 mg/kg body weight (bw)/day was reported for the supporting substance 2-thienyl 
disulfide [FL-no: 15.008] in a single-dose level 90-day study in rats. The combined estimated daily 
per capita intake of 0.14 microgram for the three candidate substances in subgroup A-Ic corresponds 
to 0.0023 microgram/kg bw/day at a body weight of 60 kg. Thus, a margin of safety of 1.3 x 105 can 
be calculated. 
On the basis of the application of the Procedure, 3-mercaptothiophene [FL-no: 15.082], 2-methyl-3-
mercaptothiophene [FL-no: 15.087] and 2-thiophenemethanethiol [FL-no: 15.108] are not expected to 
be of safety concern at their estimated levels of intake. 
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Subgroup A-II: Thiazoles 
A NOAEL of 25 mg/kg bw/day was reported for the supporting substance 5-acetyl-2,4-
dimethylthiazole [FL-no: 15.011] in a single-dose level 90-day study in rats. The combined estimated 
daily per capita intake of 2.3 microgram for the 23 candidate substances in subgroup A-II corresponds 
to 0.038 microgram/kg bw/day at a body weight of 60 kg. Thus, a margin of safety of 6.6 x 105 can be 
calculated. 
On the basis of the application of the Procedure, the 23 candidate substances in subgroup A-II are not 
expected to be of safety concern at their estimated levels of intake. 
Subgroup A-III: Benzothiazoles 
There were no valid toxicological data available on the candidate substance 2-methyl-4,5-
benzothiazole [FL-no: 15.088] nor for any sufficiently structurally related substances. The Panel 
considered that data on the supporting substance benzothiazole [FL-no: 15.016] could not be used in 
the Procedure for 2-methyl-4,5-benzothiazole, since the unsubstituted benzothiazole is anticipated to 
be metabolised differently from the substituted benzothiazole in subgroup A-III. Therefore, the Panel 
concluded that additional toxicity data are needed for 2-methyl-4,5-benzothiazole [FL-no: 15.088]. 
Subgroup B-I: Dihydrothiophenes 
No toxicological data were available on 4-hydroxy-2,5-dimethylthiophen-3(2H)-one [FL-no: 15.077] 
or for structurally related supporting substances. Therefore, the Panel concluded that additional 
toxicity data are needed for this substance. 
Subgroup B-II: Thiazolines 
The candidate substances were not evaluated through the Procedure. 
Subgroup B-III: Thiazolidines 
The candidate substances were not evaluated through the Procedure. 
Subgroup B-IV: Dithiazines 
There were no toxicological data available on the candidate substances in this subgroup and the Panel 
concluded that the data available on supporting substances could not be used for deriving a NOAEL to 
support the candidate substances in this subgroup B-IV. Accordingly, additional data are needed for 2-
butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine [FL-no: 15.042], dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine [FL-no: 15.054], 2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 
15.055], 4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-
4,6-dimethyl-1,3,5-dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135] in subgroup B-IV. 
Subgroup B-V: Dihydrothiazines 
The candidate substances were not evaluated through the Procedure. 
Subgroup B-VI: Thiadiazines 
No toxicological data were available on tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine [FL-no: 
15.129], or on structurally related supporting substances. Therefore, the Panel concluded that 
additional toxicity data are needed for this substance from subgroup B-VI. 
Summary of application of the Procedure 
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Of the 52 substances evaluated through the Procedure, in total, 26 of the candidate substances are not 
of safety concern at their estimated levels of intake based on the MSDI approach whereas for 26 
candidate substances additional data are required (see Table 2). 
6. Intake Estimations Based on the MSDI and the mTAMDI Approach 
The estimated intakes, based on the mTAMDI, for the 41 candidate substances assigned to structural 
class II and evaluated using the Procedure range from 78 to 4000 microgram/person/day. For one of 
the 41 substances, tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine [FL-no: 15.129], the mTAMDI 
value of 4000 microgram/person/day is above the threshold of concern of 540 microgram/person/day 
for a structural class II substance. 
The estimated intakes, based on the mTAMDI, for nine candidate substances assigned to structural 
class III and evaluated using the Procedure, range from 78 to 250 microgram/person/day. For four of 
these candidate substances (2-butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine [FL-no: 15.042], 
2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 2-methyl-4,5-benzothiazole [FL-
no: 15.088] and ethyl thialdine [FL-no: 15.135] the mTAMDI values are above the threshold of 
concern for structural class III substances of 90 microgram/person/day. For two candidate substances 
[FL-no: 15.057 and 15.079] assigned to structural class III, no information on use levels have been 
provided. For comparison of the MSDI and mTAMDI values, see Table 6.1.  
Further information is therefore required for the seven substances [FL-no: 15.042, 15.055, 15.057, 
15.079, 15.088, 15.129 and 15.135]. This would include more reliable intake data. On the basis of 
such additional data, these flavouring substances should be reconsidered along the steps of the 
Procedure. Following this procedure additional toxicological data might become necessary. 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
15.037 2-Acetyl-3-methylthiophene 0.18 78 Class II 540 
15.038 2-Acetyl-4-methylthiazole 0.0049 160 Class II 540 
15.039 2-Acetyl-5-methylthiazole 0.0024 160 Class II 540 
15.040 2-Acetylthiophene 2.2 78 Class II 540 
15.043 2-Butyl-5-ethylthiophene 0.0012 78 Class II 540 
15.044 2-Butylthiazole 0.011 160 Class II 540 
15.045 2-Butylthiophene 0.012 78 Class II 540 
15.050 2,5-Diethyl-4-methylthiazole 0.012 160 Class II 540 
15.051 2,5-Diethyl-4-propylthiazole 0.0012 160 Class II 540 
15.052 2,5-Diethylthiazole 0.015 160 Class II 540 
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 0.0012 160 Class II 540 
15.058 4,5-Dimethyl-2-ethylthiazole 0.015 130 Class II 540 
15.061 2,5-Dimethyl-4-ethylthiazole 0.011 160 Class II 540 
15.062 2,4-Dimethylthiazole 0.61 140 Class II 540 
15.063 2,5-Dimethylthiazole 0.0061 160 Class II 540 
15.064 2,5-Dimethylthiophene 0.23 78 Class II 540 
15.067 4-Ethyl-2-methylthiazole 0.0037 160 Class II 540 
15.068 5-Ethyl-2-methylthiazole 0.0061 220 Class II 540 
15.069 4-Ethyl-5-methylthiazole 0.012 160 Class II 540 
15.070 2-Ethyl-5-methylthiophene 0.061 78 Class II 540 
15.071 2-Ethylthiazole 0.028 160 Class II 540 
15.072 2-Ethylthiophene 0.0012 78 Class II 540 
15.074 5-Ethylthiophene-2-carbaldehyde 0.0012 78 Class II 540 
15.076 2-Hexylthiophene 0.12 78 Class II 540 
15.078 2-Isobutyl-4,5-dimethylthiazole 0.12 160 Class II 540 
15.080 2-Isopropyl-4,5-dimethylthiazole 0.012 160 Class II 540 
15.084 5-Methyl-2-pentylthiazole 0.0037 160 Class II 540 
15.085 4-Methyl-2-propionylthiazole 0.0037 160 Class II 540 
15.089 2-Methylthiazole 0.018 150 Class II 540 
15.091 2-Methylthiophene 0.019 78 Class II 540 
15.092 3-Methylthiophene 0.12 78 Class II 540 
15.093 2-Octylthiophene 0.012 160 Class II 540 
15.094 2-Pentanoylthiophene 0.0012 160 Class II 540 
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Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
15.096 sec-Pentylthiophene 0.24 160 Class II 540 
15.097 2-Propionylthiophene 0.12 160 Class II 540 
15.098 2-Propylthiazole 0.085 160 Class II 540 
15.107 Thiophene-2-carbaldehyde 0.21 78 Class II 540 
15.115 2-Isobutyl-4-methyl thiazole 0.011 160 Class II 540 
15.116 2-Acetyl-4-ethylthiazole 0.024 160 Class II 540 
15.118 4-Butylthiazole 1.3 160 Class II 540 
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 0.61 4000 Class II 540 
15.060 2,4-Dimethyl-3-thiazoline 0.012 160 Class II 540 
15.086 2-Methyl-2-thiazoline 0.24 160 Class II 540 
15.090 2-Methylthiazolidine 0.024 160 Class II 540 
15.099 2-Propylthiazolidine 0.012 160 Class II 540 
15.119 2-Isobutyl-3-thiazoline 0.011 160 Class II 540 
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine 0.0012 160 Class III 90 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 0.055 160 Class III 90 
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine 1.5  Class III 90 
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one 0.12 78 Class III 90 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 5.7  Class III 90 
15.082 3-Mercaptothiophene 0.011 78 Class III 90 
15.087 2-Methyl-3-mercaptothiophene 0.12 78 Class III 90 
15.088 2-Methyl-4,5-benzothiazole 0.0085 160 Class III 90 
15.106 Thiophene 0.12 78 Class III 90 
15.108 2-Thiophenemethanethiol 0.0073 78 Class III 90 
15.135 Ethyl thialdine 0.61 250 Class III 90 
15.114 5-Acetyl-2,3-dihydro-1,4-thiazine 0.012 160 Class III 90 
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine 0.61 4000 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of the candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
Seven of the candidate substances [FL-no: 15.060, 15.086, 15.090, 15.099, 15.114, 15.119 and 
15.133] have not been evaluated through the Procedure (see Section 5) and are therefore not 
considered together with the other 52 candidate substances evaluated in FGE.21Rev3 in the combined 
intake. 
On the basis of the reported annual production volumes in Europe (EFFA, 2004f; EFFA, 2011e; 
Flavour Industry, 2010j), the combined estimated daily per capita intakes as flavourings of the 
candidate substances in subgroups, with more than one substance from a structural class (SC), are: 
subgroup A-Ib (16 substances from SC II) 3.6 microgram; subgroup A-Ic (three substances from SC 
III) 0.14 microgram; subgroup A-II (23 substances from SC II) 2.3 microgram; and subgroup B-IV 
(five substances from SC III) 8.0 microgram. 
The 52 candidate substances evaluated through the Procedure, are structurally related to 29 supporting 
substances evaluated by the JEFCA at its 59th JECFA meeting (JECFA, 2002c). The total combined 
daily per capita intakes (in Europe) of candidate and supporting substances in each of the four 
subgroups for which supporting substances were available are: subgroup A-Ib (18 substances from SC 
II) 22 microgram; subgroup A-Ic (five substances from SC III) 0.15 microgram; subgroup A-II (36 
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substances from SC II) 500 microgram and subgroup A-III (two substances from SC III) 1.2 
microgram. 
For none of the subgroups do the total combined intakes exceed the thresholds of concern for 
compounds belonging to structural class II of 540 microgram/person/day or to structural class III of 90 
microgram/person/day. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for two candidate substances, thiophene [FL-no: 15.106] and thiophene-2-
carbaldehyde [FL-no: 15.107] and for 17 of the 29 supporting substances. The Oral LD50 values in rats 
or mice ranged from 180 to 3700 mg/kg body weight (bw). 
The acute toxicity data are summarised in Annex IV, Table IV.1 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Subacute toxicity data were available for three of the candidate substances, thiophene [FL-no: 15.106], 
2-pentylthiophene (Register name: sec-pentylthiophene) [FL-no: 15.096] and thiophene-2-
carbaldehyde [FL-no: 15.107] and for 11 supporting substances, of which nine is in the Register [FL-
no: 15.002, 15.004, 15.005, 15.008, 15.011, 15.016, 15.020, 15.024 and 15.029] and two are mixtures 
of structurally related substances (one mixture of 2-isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine and 
4-isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine, and one mixture of 2-isopropyl-4,6-dimethyldihydro-
1,3,5-dithiazine and 4-isopropyl-2,6-dimethyldihydro-1,3,5-dithiazine). 
The repeated dose toxicity studies are summarised in Annex IV, Table IV.2 
Subgroup A-Ia: Thiophene 
Based on the available data on metabolism, the toxicity of the candidate substance thiophene [FL-no: 
15.106] is considered separately from the substituted thiophenes in subgroup A-Ib. Two short-term 
toxicity tests are available on thiophene. In a study, in which thiophene was administered to groups of 
5 male rats at dose levels of 0 - 1000 mg/kg bw/day by gavage for up to 19 days, evidence of central 
nervous system toxicity was seen in higher dose groups, accompanied by haematological and clinical 
chemistry changes and increased relative liver weights (O’Donoghue, 1979). Histologically, hepatic 
necrosis was present in the 500 and 1000 mg/kg bw groups and one rat in the 1000 mg/kg bw groups 
showed thymic cortical atrophy, splenic lymphoid depletion and hypocellular bone marrow. The 
reported No Observed Adverse Effect Level (NOAEL) was 100 mg/kg bw/day. The Panel considered 
that this study was inadequate for deriving an appropriate NOAEL to be used in the Procedure because 
of the short duration and the limited study details given. 
A combined repeat dose/reproductive and developmental toxicity study, in accordance with OECD 
Test Guideline 422, has been carried out with thiophene, in which males were dosed for 42 days and 
females from 14 days before mating until Day 3 of lactation (Nagao, 2006). The full report of this 
study was in Japanese, however, a summary of the study design, results and conclusions to be drawn 
were available to the Panel in English. Groups of Sprague-Dawley rats (13/sex/dose) were 
administered thiophene via gavage at doses of 0, 25, 100 and 400 mg/kg/day. Rats of both sex showed 
ataxia after receiving 100 mg/kg of thiophene or more. Decreased food consumption and decreased 
body weight gain was observed in the 400 mg/kg group of both sexes when compared to the controls. 
Clinical chemistry revealed decreases in glucose levels and alkaline phosphatase activity and an 
increase in inorganic phosphorous levels for males in the 100 and 400 mg/kg bw/day groups. At 
necropsy, increases in relative liver weights compared with controls were statistically significant in 
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males in the 100 and 400 mg/kg bw/day groups and in females receiving 400 mg/kg bw/day. 
Histopathological evidence of liver damage was noted for males and females given 100 or 400 mg/kg 
bw/day. In both males and females receiving 400 mg/kg bw/day these included hepatocellular 
hypertrophy, inflammatory change, hepatocellular necrosis and a homogenous or vesicular 
cytoplasmic change of the hepatocytes in the central zones, while at 100 mg/kg bw/day, changes 
consisted of hepatocellular hypertrophy and some inflammatory change. A high incidence of 
histopathological changes were reported in the cerebellum for female rat given 400 mg/kg bw/day, 
including pyknosis or necrosis of the granular cells, necrosis of the laminae albae of the brain and 
degeneration or loss of Purkinje cells. Pyknosis or necrosis of the granular cells was also observed in 
one female receiving 100 mg/kg bw/day and one male receiving 400 mg/kg bw/day. In females, 
relative kidney weights were increased when compared to controls in the 100 and 400 mg/kg bw/day 
groups and a vacuolar degeneration of the tubular epithelium was observed. Based on these findings 
the authors of this study reported a NOAEL of 25 mg/kg bw/day (Nagao, 2006). The Panel considered 
that this study was inadequate for deriving an appropriate NOAEL to be used in the Procedure because 
of the short duration. According to the practice of the Panel, a minimum requirement to provide an 
adequate NOAEL for flavourings in the Procedure is a 90-day study. 
 
Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents 
In a study conducted in accordance with OECD Test Guideline 407, 2-Pentylthiopene (Register name: 
sec-pentylthiophene) [FL-no: 15.096] was administered by gavage to three groups each of five male 
and five female Sprague-Dawley Crl:CD® (SD) IGS BR strain rats, for twenty-eight days, at dose 
levels of 15, 150 or 500 mg/kg bw/day (Dhinsa et al., 2006). A control group of five males and five 
females was dosed with vehicle alone (Arachis oil). Clinical signs during treatment included increased 
salivation in all animals treated with 500 mg/kg bw/day and the majority of animals treated with 150 
mg/kg bw/day. A slight reduction in body weight gain was observed in males only treated with 500 
mg/kg bw/day, while males and females treated with 500 mg/kg bw/day showed an increase in water 
consumption. Haematologic examination revealed haemolytic anaemia in animals treated with 500 and 
150 mg/kg bw/day as evidenced by reductions in haemoglobin, haematocrit and erythrocyte count and 
evidence of reticulocytosis. Clinical chemical determinations on day 28 showed increases in bilirubin 
and alanine aminotransferase for animals of both sexes treated with 500 mg/kg bw/day, with increases 
in bilirubin also noted for both sexes animals treated with 150 mg/kg/day, and in females receiving 15 
mg/kg bw/day. Absolute and relative liver, kidney and spleen weights were increased in both sexes 
treated with 500 mg/kg bw or 150 mg/kg bw/day per day. At necropsy animals in these dose groups 
had dark and enlarged spleens. Histopathological examination revealed hepatocellular hypertrophy in 
animals of both sexes treated with 500 and 150 mg/kg bw/day. Histopathological evidence of 
extramedullary haemopoiesis and haemosiderin accumulation in the spleen of animals of either sex 
treated with 500 and 150 mg/kg bw/day, together with observation of haemosiderin deposits in the 
liver and kidney, were typical of a haemolytic anaemia, as also evidenced by the haematological 
measurements. There was also some evidence of renal damage in males and females treated with 500 
and 150 mg/kg bw/day, as evidenced in occasional animals only by tubular hypertrophy, tubular 
dilatation and tubular basophilia, pyelitis with associated hyperplasia of the renal papillary/pelvic 
epithelium (females only) and globular accumulations of eosinophilic material in the renal tubules 
(males only). Epithelial hyperplasia of the urinary bladder and associated epithelial and subepithelial 
inflammatory cell infiltrates were observed for two females treated with 500 mg/kg bw/day. 
Hypertrophy of the thyroid was reported in animals of either sex treated with 500 mg/kg bw/day, and 
for males treated with 150 mg/kg bw/day.  
In a follow-up study to evaluate the hepatic effects and the slight increase in bilirubin seen at the 
lowest dose of 15 mg/kg bw/day in the previous study, 2-pentylthiophene was administered by gavage 
to one group of five male and five female Sprague-Dawley Crl:CD® (SD) IGS BR strain rats, for 
twenty-eight consecutive days, at a dose level of 3 mg/kg/day. A control group of five males and five 
females was given vehicle alone (Arachis oil BP). Clinical signs, body weight development and food 
and water consumption monitored during the study revealed no significant differences between test 
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and control animals. Haematology and blood chemistry were evaluated for all animals at the end of the 
study and showed no significant changes. There were no treatment-related changes in spleen weights 
for treated animals in comparison to controls. No macroscopic abnormalities were detected at 
necropsy. 
The authors concluded that oral administration of 2-pentylthiophene to rats for a period of up to 
twenty eight days at a dose level of 3 mg/kg bw/day resulted in no toxicologically or haematologically 
significant effects, The NOAEL was considered to be 3 mg/kg bw/day (Marr and Watson, 2007). The 
Panel agrees with this NOAEL. 
The candidate substance thiophene-2-carbaldehyde [FL-no: 15.107] was tested in a subacute toxicity 
test, in which groups of 5 rats (sex not specified) were exposed to 0, 95 and 840 mg/kg bw/day for 11 
days (Sharp, 1979). No adverse signs or changes in behaviour were noted in treated animals. The 
reported NOAEL was 95 mg/kg bw/day.  
Data are also available from short-term tests on two supporting substances in this subgroup A-Ib 5-
methyl-2-thiophenecarbaldehyde [FL-no: 15.004] and 3-acetyl-2,5-dimethylthiophene [FL-no: 
15.024], administered to male and female rats for 14 days at 10 mg/kg bw/day (Gill and Van Miller, 
1987b). Both substances produced minor body weight changes in both sexes and organ weight 
changes in males only.  
The Panel considered that the studies available on the candidate substance in this subgroup, 2-
Pentylthiopene (Register name: sec-pentylthiophene) [FL-no: 15.096] and thiophene-2-carbaldehyde 
[FL-no: 15.107], together with the two studies on supporting substances, were inadequate for deriving 
an appropriate NOAEL to be used in the Procedure because of the short durations of these studies. 
According to the practice of the Panel, a minimum requirement to provide an adequate NOAEL for 
flavourings in the Procedure is a 90-day study. 
Subgroup A-Ic: Thiophenes with thiol-containing ring substituents 
No toxicity data were available for the three candidate substances in this subgroup [FL-no: 15.082, 
15.087 and 15.108]. The supporting substance 2-thienyl disulfide (2,2’-dithiodithiophene) [FL-no: 
15.008] was tested in a 90-day dietary feeding study in male and female rats at a single dose level of 
0.29 mg/kg bw/day (Morgareidge and Oser, 1970g). Body weight changes, food consumption, 
haematological and clinical chemistry parameters were assessed, urinalysis was undertaken and a 
comprehensive range of tissues were examined histopathologically. No changes were detected in any 
of the parameters assessed, and accordingly a NOAEL of 0.29 mg/kg bw/day could be established. 
Subgroup A-II: Thiazoles 
There were no subacute, subchronic or chronic toxicity studies on any of the 23 candidate thiazoles in 
subgroup A-II.  
A 90-day dietary feeding study was carried out on the supporting substance 5-acetyl-2,4-
dimethylthiazole [FL-no: 15.011] in male (23) and female (23) rats, at a single dose level of 
approximately 25 mg/kg bw/day (Shellenberger, 1971d). Body weight, food consumption, 
haematological and clinical chemistry parameters were assessed, urinalysis was undertaken and a 
comprehensive range of tissues were examined histopathologically. No changes were detected in any 
of the parameters assessed and accordingly a NOAEL of 25 mg/kg bw/day could be established. 
In a 90-day study on the supporting substance 2-acetylthiazole [FL-no: 15.020], male rats (10/group) 
were fed diets containing 0, 100, 1000 or 10,000 mg/kg test substance, reported to be equivalent to an 
average daily intake of 0, 5, 50 and 500 mg/kg bw/day (Wheldon et al., 1970). The dose level in the 
highest dose group was increased to 20,000 mg/kg at week 6. Test substance-related changes at 10,000 
- 20,000 mg/kg included reduced body weight gain, increased relative liver, adrenal and thyroid 
weights and minimal fatty changes in the liver. The authors reported a NOAEL of 50 mg/kg bw/day. 
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However, due to limitations in the study design and reporting, the Panel concluded that this NOAEL 
could not be used in the Procedure. 
Two further 90-day studies were carried out at single dose levels with the supporting substances 2-
methyl-5-methoxythiazole [FL-no: 15.002] and 2,4-dimethyl-5-vinylthiazole [FL-no: 15.005] 
(Posternak et al., 1975). Due to limitations in reporting of experimental details and results, the Panel 
concluded that these studies could not be used to derive a NOAEL to be used in the Procedure. 
Oral intakes of up to 500 mg thiamine/day (8 mg/kg bw/day in a 60 kg individual) have been reported 
to have no adverse effects in humans (SCF, 2001). 
Subgroup A-III: Benzothiazoles 
There were no toxicological studies available on the candidate substance 2-methyl-4,5-benzothiazole 
[FL-no: 15.088] in subgroup A-III. The Panel concluded that data on the supporting substance 
benzothiazole [FL-no: 15.016] could not be used in the Procedure for 2-methyl-4,5-benzothiazole, 
since the unsubstituted benzothiazole is anticipated to be metabolised differently from the substituted 
benzothiazole in subgroup A-III (see Section 4 and Annex III). 
Subgroup B-I: Dihydrothiophenes 
There were no toxicological data available on the candidate substance 4-hydroxy-2,5-
dimethylthiophen-3(2H)-one [FL-no: 15.077] nor were there any data on supporting substances for 
subgroup B-I. 
Subgroup B-II: Thiazolines 
There were no toxicological data available for the three candidate substances in this subgroup. The 
supporting substance 2-(sec-butyl)-4,5-dimethyl-3-thiazoline [FL-no: 15.029] was tested in a 90-day 
dietary feeding study in male and female rats (15/sex) at one dose level of approximately 1 mg/kg 
bw/day (Babish and Re, 1978). Body weight changes, food consumption, limited haematological and 
clinical chemistry parameters were assessed, urinalysis was undertaken and a comprehensive range of 
tissues were examined histopathologically. No changes were detected in any of the parameters 
assessed and accordingly a NOAEL of 1 mg/kg bw/day could be established. 
Subgroup B-III: Thiazolidines 
There were no toxicological data available on the candidate substances 2-methyl thiazolidine and 2-
propyl thiazolidine [FL-no: 15.090 and 15.099] nor were there any data on structurally related 
substances for subgroup B-III. 
Subgroup B-IV: Dithiazines 
There were no toxicological data available on the six candidate substances in subgroup B-IV [FL-no: 
15.042, 15.054, 15.055 15.057, 15.079 and 15.135]. Short-term toxicity tests are available on the 
mixture 2-isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-isobutyl-2,6-dimethyldihydro-1,3,5-
dithiazine (Rush, 1989a) and the mixture 2-isopropyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-
isopropyl-2,6-dimethyldihydro-1,3,5-dithiazine (Rush, 1989b). The mixtures were incorporated in the 
diet of Sprague-Dawley rats (5/sex/group) intake of approximately 10 mg/kg bw/day over a period of 
14 days. No treatment-related effects were seen. The Panel considered that these studies were 
inadequate for deriving a NOAEL to be used in the Procedure, because of the short duration of the 
studies. 
Subgroup B-V: Dihydrothiazines 
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There were no toxicological data available on the candidate substances 6-acetyl-2,3-dihdro-1,4-
thiazine [FL-no: 15.114] (Register name: 5-acetyl-2,3-dihydro-1,4-thiazine) or 5-acetyl-2,3-dihdro-
1,4-thiazine [FL-no: 15.133] nor were there any data on supporting substances for subgroup B-V.  
Subgroup B-VI: Thiadiazines 
No toxicological data were available on tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine [FL-no: 
15.129] or on structurally related supporting substances.  
The repeated dose toxicity studies are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
As described in Section 8.2, a combined repeat dose/reproductive and developmental toxicity study, in 
accordance with OECD Test Guideline 422, has been carried out with thiophene, in which males were 
dosed for 42 days and females from 14 days before mating until day 3 of lactation (Nagao, 2006). The 
full report of this study was in Japanese, however a summary of the study design, results and 
conclusions to be drawn were available to the Panel in English.  
Groups of Sprague-Dawley Rats (13/sex/dose) were administered thiophene via gavage at dose levels 
of 0, 25, 100, or 400 mg/kg bw/day. No adverse effects on copulation, ovulation, or fertility in 
treatment groups were observed when compared to the control groups. However, in each group, 
abnormal parturition was found. Females in the 100 or 400 mg/kg bw/day group, showing evidence of 
histopathological change in the cerebellum, exhibited abnormal lactation. Pups born to the 400 mg/kg 
bw/day group showed reduced birth weights and viability decreased at postnatal day 4. No 
morphological abnormalities associated with the administration of thiophene were found in any pup. 
With respect to effects on reproduction, the NOAEL was suggested by the authors to be 400 mg/kg 
bw/day for males and 25 mg/kg bw/day for females (Nagao, 2006). 
No other developmental toxicity or reproductive toxicity studies were available for any of the 56 
candidate substances or for any of the 29 supporting substances evaluated by the JECFA. 
 
The developmental/reproductive toxicity study is summarised in Annex IV, Table IV.3. 
 
8.4. Genotoxicity Studies 
Genotoxicity data were provided for 12 of the candidate substances. These 12 substances belong to 
subgroup A-Ia: thiophene [FL-no: 15.106]; subgroup A-Ib: 2-methylthiophene [FL-no: 15.091], 3-
methylthiophene [FL-no: 15.092], 2,5-dimethylthiophene [FL-no: 15.064], 2-acetylthiophene [FL-no: 
15.040], 2-acetyl-3-methylthiophene [FL-no: 15.037], thiophene-2-carbaldehyde [FL-no: 15.107], 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074]; subgroup A-II: 2,4-dimethylthiazole [FL-no: 15.062]; 
subgroup A-III: 2-methyl-4,5-benzothiazole [FL-no: 15.088]; subgroup B-III: 2-methylthiazolidine 
[FL-no: 15.090] and 2-propylthiazolidine [FL-no: 15.099]. There were also mutagenicity data on four 
supporting substances and on four other structurally related substances. All available information on 
genotoxicity of the 12 candidate and the four supporting substances and of four other structurally 
related substances is based upon in vitro studies only. 
Subgroup A-I: 
Thiophene [FL-no: 15.106], 2-methylthiophene [FL-no: 15.091], 3-methyl-thiophene [FL-no: 15.092] 
and 2,5-dimethylthiophene [FL-no: 15.064] were reported to be negative in microbial mutagenicity 
assays. 2-Acetylthiophene [FL-no: 15.040] was negative in microbial tests, using Salmonella 
typhimurium strains TA98 and TA100, with and without metabolic activation and in the SOS 
chromotest with metabolic activation. 2-Acetylthiophene was reported to be positive without 
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metabolic activation in the SOS Escherichia coli chromotest (Mosier et al., 2003). In the same study, 
2-acetyl-3-methylthiophene [FL-no: 15.037], thiophene-2-carbaldehyde [FL-no: 15.107] and 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074] gave positive results without metabolic activation in 
the SOS E. coli chromotest. The concentrations tested were not reported for any of the substances 
subjected to the SOS E. coli chromotest (Mosier et al., 2003). The Panel considered the endpoint of 
this test inappropriate for the estimation of genotoxic potential. The supporting substance 5-methyl-2-
thiophenecarbaldehyde [FL-no: 15.004] was negative in a microbial mutagenicity assay. 
Thiophene was tested in accordance to OECD guidelines in a bacterial reverse mutation test in strains 
of S. typhimurium and in strain WP2 uvrA of E. coli. No evidence of mutagenic response was reported 
when strains TA100, TA1535, TA98, and TA1537 of S. typhimurium were incubated at concentrations 
of 0, 78.1, 156, 313, 625, 1250, 2500 and 5000 μg/plate with and without S9 metabolic activation. 
Toxicity was observed at 1250 μg/plate in TA1537, and 2500 μg/plate in strains TA100, TA1535 and 
TA98 also with and without metabolic activation. Toxicity was observed at 5000 μg/plate in WP2 with 
and without S9 metabolic activation (Shibuya, 2006). 
In a chromosomal aberration test, thiophene was tested on Chinese hamster lung cells in accordance 
with Japanese Guidelines. No chromosomal aberrations or polyploidy was reported when incubated 
with concentrations of 0, 210, 420, 840 μg/mL of thiophene, with and without metabolic activity 
(Tanaka, 2006). 
Subgroup A-II: 
2,4-Dimethylthiazole [FL-no: 15.062] was reported to be negative in microbial assays, using S. 
typhimurium, but only in strain TA100 and only in the absence of metabolic activation (Voogd et al., 
1983). Two supporting substances, 4,5-dimethylthiazole [FL-no: 15.017] and 4-methylthiazole [FL-
no: 15.035] were negative in microbial mutagenicity assays. 
Subgroup A-III: 
2-Methyl-4,5-benzothiazole [FL-no: 15.088] was reported to be negative in an Ames test but only a 
summary report was available (Longfellow, 1998a). The supporting substance benzothiazole [FL-no: 
15.016] was negative in microbial mutagenicity assay and in the mouse lymphoma test. 
Subgroups B-I and B-II: 
No genotoxicity information was available for any candidate or supporting substances in these 
subgroups. However, considering the structural similarities between the thiazolines in subgroup B-II 
and the thiazolidines in subgroup B-III, the Panel also concluded that the thiazolines [FL-no: 15.060, 
15.086 and 15.119] could not be evaluated through the Procedure (see Subgroup B-III below). 
Subgroup B-III: 
The two candidate substances 2-methylthiazolidine [FL-no: 15.090] and 2-propylthiazolidine [FL-no: 
15.099] as well as the structurally related ethyl, isopropyl, n-butyl and isobutyl thiazolidine have all 
been reported to be positive in the Ames tests (TA98 and TA100) (Mihara and Shibamoto, 1980). 
Owing to limited reporting, the data could not be properly evaluated. Nevertheless, these reports do 
raise the possibility of a genotoxic potential of these thiazolidines. Accordingly, it was concluded not 
to evaluate the candidate substances 2-methylthiazolidine and 2-propylthiazolidine through the 
Procedure. 
Subgroup B-IV:  
No genotoxicity information was available for any candidate or supporting substance in this subgroup.  
Subgroup B-V:  
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The two candidate substances 6-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.114] (Register name: 5-
acetyl-2,3-dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.133] are alpha,beta 
unsaturated ketones i.e. they have a structural alert for genotoxicity (EFSA, 2008b) and as there are no 
genotoxicity data available a concern for genotoxicity cannot be ruled out. 
Subgroup B-VI:  
No genotoxicity information was available for any candidate or supporting substance in this subgroup.  
Overall conclusion on genotoxicity: 
It is concluded that the genotoxicity data are limited and that genotoxicity could not be assessed 
adequately for the flavouring substances in the present revision of FGE.21, Revision 3. However, 
except for the two dihydrothiazines, 6-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.114] (Register 
name: 5-acetyl-2,3-dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.133], the 
two thiazolidines 2-methylthiazolidine [FL-no: 15.090] and 2-propylthiazolidine [FL-no: 15.099] and 
the three structurally related thiazolines 2-methyl-2-thiazoline [FL-no: 15.086], 2,4-dimethyl-3-
thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the genotoxicity data available 
do not preclude the evaluation of the remaining 49 candidate substances using the Procedure.  
9. Conclusions 
All candidate substances are five- or six-member sulphur-containing heterocyclic compounds, some of 
which also contain nitrogen. They belong to chemical groups 29 and 30 and they can be divided into 
two main groups, (A) those with an aromatic ring (44 candidate substances) and (B) those with a non-
aromatic ring structure (15 candidate substances). Except for thiophene, all are ring-substituted with 
one or more of the following substituents: alkyl, alkenyl, aryl, alcohol, keto, thio. For assessment 
purposes, the following further subdivision of groups (A) and (B) has been made: 
Group (A): Aromatic:  
Subgroup A-Ia: Thiophene.  
Subgroup A-Ib: Thiophene derivatives with non-thiol-containing ring substituents.  
Subgroup A-Ic: Thiophene derivatives with thiol-containing ring substituents.  
Subgroup A-II: Thiazole derivatives.  
Subgroup A-III: Benzothiazoles.  
Group (B): Non aromatic: 
Subgroup B-I: Dihydrothiophenes.  
Subgroup B-II: Thiazolines.  
Subgroup B-III: Thiazolidines.  
Subgroup B-IV: Dithiazine derivatives.  
Subgroup B-V: Dihydrothiazines.  
Subgroup B-VI: Thiadiazine derivatives. 
Twelve candidate substances possess one or more chiral centres. For four of these substances [FL-no: 
15.042, 15.057, 15.079 and 15.135] the stereoisomeric composition has not been specified sufficiently.  
Forty-six of the candidate substances belong to structural class II and 13 belong to structural class III. 
Forty-four of the candidate substances have been reported to occur naturally in a wide range of foods. 
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According to the default MSDI approach, the flavouring substances in this group have intakes in 
Europe ranging from 0.0012 to 5.7 microgram/capita/day, which are below the thresholds of concern 
values for structural class II (540 microgram/person/day) and structural class III (90 
microgram/person/day) substances. 
 
On the basis of the reported annual production volumes of the candidate substances as flavourings in 
Europe, the combined estimated daily per capita intakes, per subgroup and structural class range from 
0.14 to 8.0 microgram. For none of the subgroups do the total combined intakes exceed the thresholds 
of concern of 540 microgram/person/day or of 90 microgram/person/day for structural class II and III, 
respectively. 
The candidate substances are structurally related to 29 supporting substances evaluated by the JEFCA 
at its 59th JECFA meeting (JECFA, 2002c). The total combined daily per capita intakes (in Europe) of 
candidate and supporting substances in each of the four subgroups for which supporting substances 
were available are: subgroup A-Ib (18 substances from class II) 22 microgram; subgroup A-Ic (five 
substances from class III) 0.15 microgram; subgroup A-II (36 substances from class II) 500 microgram 
and subgroup A-III (two substances from class III) 1.2 microgram. For none of the subgroups do the 
combined intakes exceed the thresholds of concern for compounds belonging to structural class II of 
540 microgram/person/day or to structural class III of 90 microgram/person/day. 
It is concluded that the genotoxicity data are limited and that genotoxicity could not be assessed 
adequately for the flavouring substances in FGE.21Rev3. However, except for the two 
dihydrothiazines, 6-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.114] (Register name: 5-acetyl-2,3-
dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.133], two thiazolidines, 2-
methylthiazolidine [FL-no: 15.090] and 2-propylthiazolidine [FL-no: 15.099] and the three 
structurally related thiazolines, 2-methyl-2-thiazoline [FL-no: 15.086], 2,4-dimethyl-3-thiazoline [FL-
no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the genotoxicity data available do not 
preclude the evaluation of the remaining 52 candidate substances using the Procedure. 
The metabolism data available were insufficient to allow conclusions about the metabolic fate of the 
candidate substances, and accordingly the 52 candidate substances evaluated through the Procedure 
could not be anticipated to be metabolised to innocuous products. However, the Panel concluded that 
the evidence of binding to macromolecules from possible formation of electrophilic metabolites, (e.g. 
by either ring scission or S-oxidation) was not sufficiently strong to preclude the application of the 
Procedure. 
Toxicological data on both candidate and supporting substances were limited and did not include 
information about chronic or reproductive toxicity, with the exception of a combined repeat dose and 
reproduction and developmental toxicity study on thiophene [FL-no: 15.106]. Valid toxicological data 
which could provide an adequate margin of safety compared to the intakes from use as flavouring 
substances were only available for the 26 candidate substances from subgroup A-Ic (thiophenes with 
thiol-containing ring substituents) and subgroup A-II (thiazoles). 
For the remaining 26 candidate substances belonging to the subgroups of thiophene itself (A-Ia), 
thiophenes with non-thiol-containing ring substituents (A-Ib), benzothiazoles (A-III), 
dihydrothiophenes (B-I), dithiazines (B-IV) and thiadiazines (B-VI), the Panel concluded that there 
were insufficient data available to provide margins of safety from their use as flavouring substances 
and that additional toxicity data are needed. 
It is considered that 26 candidate substances evaluated through the Procedure [FL-no: 15.038, 15.039, 
15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 
15.078, 15.080, 15.082, 15.084, 15.085, 15.087, 15.089, 15.098, 15.108, 15.115, 15.116 and 15.118] 
are not of safety concern at their estimated levels of intake based on the MSDI approach, whereas for 
26 candidate substances [FL-no: 15.037, 15.040, 15.042, 15.043, 15.045, 15.054, 15.055, 15.057, 
15.064, 15.070, 15.072, 15.074, 15.076, 15.077, 15.079, 15.088, 15.091, 15.092, 15.093, 15.094, 
15.096, 15.097, 15.106, 15.107, 15.129 and 15.135], additional toxicological data are required. 
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The estimated intakes, based on the mTAMDI, for the 41 candidate substances assigned to structural 
class II and evaluated using the Procedure, range from 78 to 4000 microgram/person/day. For one of 
these substances, [FL-no: 15.129], the mTAMDI value of 4000 microgram/person/day is above the 
threshold of concern of 540 microgram/person/day for structural class II. The estimated intakes based 
on the mTAMDI of the nine candidate substances assigned to structural class III and evaluated 
through the Procedure ranged from 78 to 250 microgram/person/day. For four of the candidate 
substances, [FL-no: 15.042, 15.055 15.088 and 15.135] the estimated intakes are above the threshold 
of concern for structural class III substances of 90 microgram/person/day. For two candidate 
substances, [FL-no: 15.057 and 15.079], assigned to structural class III, no use levels were provided at 
all. Therefore, more reliable exposure data are required for [FL-no: 15.042, 15.055, 15.057, 15.079, 
15.088, 15.129 and 15.135]. On the basis of such additional data, these flavouring substances should 
be re-evaluated using the Procedure 
In order to determine whether the conclusion for the 52 candidate substances which have been 
evaluated using the Procedure can be applied to the materials of commerce, it is necessary to consider 
the available specifications. Adequate specifications including purity and identity for the materials of 
commerce have been provided for 47 flavouring substances evaluated through the Procedure. 
Information on stereoisomerism is incomplete for four of the substances, [FL-no: 15.042, 15.057, 
15.079 and 15.135] and for one substance, [FL-no: 15.129], an identity test is missing.  
Thus, the final evaluation of the materials of commerce cannot be performed for the five 
substances [FL-no: 15.042, 15.057, 15.079, 15.129 and 15.135], pending further information on 
stereoisomerism and/or identity test. 
For 26 flavouring substances evaluated through the Procedure [FL-no: 15.037, 15.040, 15.042, 15.043, 
15.045, 15.054, 15.055, 15.057, 15.064, 15.070, 15.072, 15.074, 15.076, 15.077, 15.079, 15.088, 
15.091, 15.092, 15.093, 15.094, 15.096, 15.097, 15.106, 15.107, 15.129 and 15.135] the Panel 
considered that additional toxicity data are needed. Furthermore, for seven substances [FL-no: 15.060, 
15.086, 15.090, 15.099, 15.114, 15.119 and 15.133] the Panel concluded that additional genotoxicity 
data are required. 
For the remaining 26 flavouring substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 
15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.080, 15.082, 15.084, 
15.085, 15.087, 15.089, 15.098, 15.108, 15.115, 15.116 and 15.118], evaluated using the Procedure, 
the Panel concluded that they would present no safety concern at their estimated levels of intake based 
on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN FGE 21REV3 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
15.037 
 
2-Acetyl-3-methylthiophene 
S
O  
11590 
13679-72-6 
Liquid 
C7H8OS 
140.20 
Practically insoluble or 
insoluble 
Freely soluble 
216 
 
MS 
95 % 
1.558-1.564 
1.130-1.136 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.038 
 
2-Acetyl-4-methylthiazole 
N
S
O  
11589 
7533-07-5 
Solid 
C6H7NOS 
141.19 
Practically insoluble or 
insoluble 
Freely soluble 
95 (16 hPa) 
34 
MS 
95 % 
n.a. 
n.a. 
 
 
15.039 
 
2-Acetyl-5-methylthiazole 
N
S
O  
 
59303-17-2 
Solid 
C6H7NOS 
141.19 
Practically insoluble or 
insoluble 
Freely soluble 
93 (16 hPa) 
30 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.040 
 
2-Acetylthiophene 
S
O  
11728 
88-15-3 
Solid 
C6H6OS 
126.17 
Practically insoluble or 
insoluble 
Freely soluble 
213 
34 
MS 
98 % 
1.563-1.569 
1.164-1.171 
 
 
15.042 
 
2-Butyl-4-
methyl(4H)pyrrolidino[1,2d]-1,3,5-
dithiazine 
S N
S
 
 
 
132344-97-9 
Solid 
C11H21NS2 
231.42 
Practically insoluble or 
insoluble 
Freely soluble 
304 
164 
NMR 
95 % 
n.a. 
n.a. 
Mixture of 
diastereoisomers (EFFA, 
2010a). Composition of 
stereoisomeric mixture to 
be specified.  
CASrn in Register does 
not specify stereo-
isomeric composition. 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.043 
 
2-Butyl-5-ethylthiophene S
 
 
11596 
54411-06-2 
Solid 
C10H16S 
168.30 
Practically insoluble or 
insoluble 
Freely soluble 
231 
54 
MS 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
15.044 
 
2-Butylthiazole 
N
S
 
 
11597 
37645-61-7 
Solid 
C7H11NS 
141.23 
Practically insoluble or 
insoluble 
Freely soluble 
212 
79 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.045 
 
2-Butylthiophene S
 
 
 
1455-20-5 
Liquid 
C8H12S 
140.24 
Practically insoluble or 
insoluble 
Freely soluble 
182 
 
MS 
95 % 
1.504-1.510 
0.951-0.957 
 
 
15.050 
 
2,5-Diethyl-4-methylthiazole 
N
S  
 
41981-71-9 
Solid 
C8H13NS 
155.26 
Practically insoluble or 
insoluble 
Freely soluble 
85 (20 hPa) 
115 
MS 
95 % 
n.a. 
n.a. 
 
 
15.051 
 
2,5-Diethyl-4-propylthiazole 
N
S  
 
4276-68-0 
Solid 
C10H17NS 
183.31 
Practically insoluble or 
insoluble 
Freely soluble 
72 (21 hPa) 
139 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.052 
 
2,5-Diethylthiazole 
N
S
 
 
 
15729-76-7 
Solid 
C7H11NS 
141.23 
Practically insoluble or 
insoluble 
Freely soluble 
187 
92 
MS 
95 % 
n.a. 
n.a. 
 
 
15.054 
 
Dihydro-2,4,6-triethyl-1,3,5(4H)-
dithiazine 
S NH
S  
 
54717-17-8 
Solid 
C9H19NS2 
205.38 
Practically insoluble or 
insoluble 
Freely soluble 
287 
188 
MS 
95 % 
n.a. 
n.a. 
Mixture of 
diastereoisomers (EFFA, 
2010a). Mixture of 
isomers ((R/R), (R/S), 
(S/R) & (S/S) at equal 
ratio, i.e. 25 % of each) 
(EFFA, 2011f). 
15.055 
 
2,4-
Dimethyl(4H)pyrrolidino[1,2e]-
1,3,5-dithiazine 
S N
S
4321 
 
116505-60-3 
Solid 
C8H15NS2 
189.34 
Practically insoluble or 
insoluble 
Freely soluble 
235 
130 
MS 
95 % 
n.a. 
n.a. 
Register name to be 
changed to [2S-
(2α,4α,8αβ)] 2,4-
Dimethyl(4H)pyrrolidino[
1,2e]-1,3,5-dithiazine 
(EFFA, 2010a).  
15.057 
  
4,6-Dimethyl-2-(1-
methylethyl)dihydro-1,3,5-
dithiazine  6) 
S
N
H
S
3782 
 
104691-40-9 
Liquid 
C8H17NS2 
191.36 
Slightly soluble 
Soluble 
109 (0.23hPa) 
 
MS 
71 % 
1.496-1.500 
0.951-0.959 
At least 44 % 2-
Isopropyl-4,6-dimethyl 
and 27 % 4-Isopropyl-
2,6-dimethyl; sec comp. 
at least 24 % 2,4,6-
Trimethyldihydro--; 6-
Methyl-2,4-diisopropyl-; 
4-Methyl-2,6-diisopropyl-
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
, 2,4,6-Triisopropyl-
dihydro-1,3,5-dithiazine 
(EFFA, 2011h). 
15.058 
 
4,5-Dimethyl-2-ethylthiazole 
N
S  
 
873-64-3 
Solid 
C7H11NS 
141.23 
Practically insoluble or 
insoluble 
Freely soluble 
185 
104 
MS 
96 % 
n.a. 
n.a. 
 
 
15.060 
 
2,4-Dimethyl-3-thiazoline 
N
S  
 
60755-05-7 
Solid 
C5H9NS 
115.19 
Practically insoluble or 
insoluble 
Freely soluble 
52 (15 hPa) 
102 
MS 
95 % 
n.a. 
n.a. 
Racemate (EFFA, 2010a). 
15.061 
 
2,5-Dimethyl-4-ethylthiazole 
N
S  
 
32272-57-4 
Solid 
C7H11NS 
141.23 
Practically insoluble or 
insoluble 
Freely soluble 
185 
104 
MS 
95 % 
n.a. 
n.a. 
 
 
15.062 
 
2,4-Dimethylthiazole 
N
S  
11605 
541-58-2 
Solid 
C5H7NS 
113.18 
Practically insoluble or 
insoluble 
Freely soluble 
145 
69 
MS 
95 % 
n.a. 
n.a. 
 
 
15.063 
 
2,5-Dimethylthiazole 
N
S
 
 
 
4175-66-0 
Solid 
C5H7NS 
113.18 
Practically insoluble or 
insoluble 
Freely soluble 
152 
69 
MS 
95 % 
n.a. 
n.a. 
 
 
15.064 
 
2,5-Dimethylthiophene S
 
 
11609 
638-02-8 
Liquid 
C6H8S 
112.19 
Practically insoluble or 
insoluble 
Freely soluble 
135 
 
MS 
95 % 
1.508-1.514 
0.982-0.988 
 
 
15.067 
 
4-Ethyl-2-methylthiazole 
N
S  
 
32272-48-3 
Solid 
C6H9NS 
127.20 
Practically insoluble or 
insoluble 
Freely soluble 
91 (89 hPa) 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
15.068 
 
5-Ethyl-2-methylthiazole 
N
S
 
 
 
19961-52-5 
Solid 
C6H9NS 
127.20 
Practically insoluble or 
insoluble 
Freely soluble 
170 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
FGE.21Rev3
 
 
33 EFSA Journal 2012; 10(2):2457 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
15.069 
 
4-Ethyl-5-methylthiazole 
N
S  
 
52414-91-2 
Solid 
C6H9NS 
127.20 
Practically insoluble or 
insoluble 
Freely soluble 
174 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
15.070 
 
2-Ethyl-5-methylthiophene S
 
 
 
40323-88-4 
Liquid 
C7H10S 
126.22 
Practically insoluble or 
insoluble 
Freely soluble 
158 
 
MS 
97 % 
1.503-1.509 
0.963-0.970 
 
 
15.071 
 
2-Ethylthiazole 
N
S
 
 
 
15679-09-1 
Liquid 
C5H7NS 
113.18 
Practically insoluble or 
insoluble 
Freely soluble 
148 
 
MS 
95 % 
1.511-1.517 
1.058-1.064 
 
 
15.072 
 
2-Ethylthiophene S
 
 
11614 
872-55-9 
Liquid 
C6H8S 
112.19 
Practically insoluble or 
insoluble 
Freely soluble 
133 
 
MS 
95 % 
1.510-1.516 
0.989-0.995 
 
 
15.074 
 
5-Ethylthiophene-2-carbaldehyde 
S
O  
 
36880-33-8 
Solid 
C7H8OS 
140.20 
Practically insoluble or 
insoluble 
Freely soluble 
104 (12 hPa) 
62 
MS 
95 % 
n.a. 
n.a. 
 
 
15.076 
 
2-Hexylthiophene S
 
4137 
11616 
18794-77-9 
Solid 
C10H16S 
168.30 
Practically insoluble or 
insoluble 
Freely soluble 
92 (13 hPa) 
41 
MS 
95 % 
n.a. 
n.a. 
 
 
15.077 
 
4-Hydroxy-2,5-dimethylthiophen-
3(2H)-one 
S
HO O
 
 
26494-10-0 
Solid 
C6H8O2S 
144.19 
Practically insoluble or 
insoluble 
Freely soluble 
296 
133 
MS 
95 % 
n.a. 
n.a. 
Racemate (EFFA, 2010a).  
Substance not supported 
by Industry (EFFA, 
2009c). 
15.078 
 
2-Isobutyl-4,5-dimethylthiazole 
N
S  
11617 
53498-32-1 
Solid 
C9H15NS 
169.29 
Practically insoluble or 
insoluble 
Freely soluble 
267 
112 
MS 
97 % 
n.a. 
n.a. 
 
 
15.079 
 
2-Isobutyldihydro-4,6-dimethyl-
1,3,5-dithiazine  6) 
S
N
H
S
 
3781 
 
101517-87-7 
Liquid 
C9H19NS2 
205.39 
Slightly soluble 
Soluble 
115 (0.33 hPa) 
 
MS 
82 % 
1.488-1.492 
0.961-0.967 
At least 64 % 2-isobutyl-
4,6-dimethyl and 18 % 4-
Isobutyl-2,6-dimethyl; 
sec. components at least 
13 % 2,4,6-trimethyl-; 
2,4-diisobutyl-6-methyl-; 
2,6-dimethyl-4-
butyldihydro-1,3,5-
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
dithiazine; substituted 
1,3,5-thiadiazine.(EFFA, 
2011h). 
15.080 
 
2-Isopropyl-4,5-dimethylthiazole 
N
S
 
 
53498-30-9 
Solid 
C8H13NS 
155.26 
Practically insoluble or 
insoluble 
Freely soluble 
244 
101 
MS 
95 % 
n.a. 
n.a. 
 
 
15.082 
 
3-Mercaptothiophene S
SH
 
 
7774-73-4 
Liquid 
C4H4S2 
116.20 
Slightly soluble 
Freely soluble 
171 
 
MS 
95 % 
1.617-1.623 
1.248-1.254 
 
 
15.084 
 
5-Methyl-2-pentylthiazole 
N
S
 
 
 
86290-21-3 
Solid 
C9H15NS 
169.26 
Practically insoluble or 
insoluble 
Freely soluble 
262 
114 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.085 
 
4-Methyl-2-propionylthiazole 
N
S
O  
11622 
13679-83-9 
Solid 
C7H9NOS 
155.21 
Practically insoluble or 
insoluble 
Freely soluble 
86 (12 hPa) 
142 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.086 
 
2-Methyl-2-thiazoline 
N
S
 
 
 
2346-00-1 
Solid 
C4H7NS 
101.17 
Slightly soluble 
Freely soluble 
144 
62 
MS 
95 % 
n.a. 
n.a. 
 
 
15.087 
 
2-Methyl-3-mercaptothiophene S
SH
 
 
2527-76-6 
Solid 
C5H6S2 
130.22 
Slightly soluble 
Freely soluble 
73 (15 hPa) 
27 
MS 
95 % 
n.a. 
n.a. 
 
 
15.088 
 
2-Methyl-4,5-benzothiazole 
N
S  
 
120-75-2 
Liquid 
C8H7NS 
149.21 
Practically insoluble or 
insoluble 
Freely soluble 
238 
 
MS 
95 % 
1.612-1.618 
1.173-1.179 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.089 
 
2-Methylthiazole 
N
S
 
 
11626 
3581-87-1 
Liquid 
C4H5NS 
99.15 
Slightly soluble 
Freely soluble 
128 
 
MS 
95 % 
1.511-1.517 
1.109-1.116 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
15.090 
 
2-Methylthiazolidine 
NH
S
 
 
 
24050-16-6 
Liquid 
C4H9NS 
103.18 
Slightly soluble 
Freely soluble 
160 
 
MS 
95 % 
1.522-1.528 
1.519-1.525 
Racemate (EFFA, 2010a). 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.091 
 
2-Methylthiophene S
 
 
11631 
554-14-3 
Liquid 
C5H6S 
98.16 
Practically insoluble or 
insoluble 
Freely soluble 
112 
 
MS 
97 % 
1.516-1.523 
1.013-1.022 
 
 
15.092 
 
3-Methylthiophene S  
11632 
616-44-4 
Liquid 
C5H6S 
98.16 
Practically insoluble or 
insoluble 
Freely soluble 
115 
 
MS 
95 % 
1.514-1.520 
1.018-1.024 
 
 
15.093 
 
2-Octylthiophene S  
 
880-36-4 
Solid 
C12H20S 
196.35 
Practically insoluble or 
insoluble 
Freely soluble 
259 
64 
MS 
95 % 
n.a. 
n.a. 
 
 
15.094 
 
2-Pentanoylthiophene 
S
O  
 
53119-25-8 
Solid 
C9H12OS 
168.26 
Practically insoluble or 
insoluble 
Freely soluble 
257 
80 
MS 
95 % 
n.a. 
n.a. 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.096 
 
sec-Pentylthiophene S
 
4387 
11634 
4861-58-9 
Liquid 
C9H14S 
154.27 
Practically insoluble or 
insoluble 
Freely soluble 
201 
 
MS 
95 % 
1.495-1.501 
0.940-0.946 
Register name to be 
changed to 2-
Pentylthiophene (EFFA). 
15.097 
 
2-Propionylthiophene 
S
O  
11635 
13679-75-9 
Solid 
C7H8OS 
140.20 
Practically insoluble or 
insoluble 
Freely soluble 
225 
57 
MS 
95 % 
n.a. 
n.a. 
 
 
15.098 
 
2-Propylthiazole 
N
S
 
 
 
17626-75-4 
Solid 
C6H9NS 
127.20 
Practically insoluble or 
insoluble 
Freely soluble 
172 
78 
MS 
95 % 
n.a. 
n.a. 
 
 
15.099 
 
2-Propylthiazolidine 
NH
S
 
 
 
24050-10-0 
Solid 
C6H13NS 
131.24 
Practically insoluble or 
insoluble 
Freely soluble 
75 (13 hPa) 
84 
MS 
95 % 
n.a. 
n.a. 
Racemate (EFFA, 2010a). 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.106 
 
Thiophene S
 
 
11647 
110-02-1 
Liquid 
C4H4S 
84.14 
Practically insoluble or 
insoluble 
Freely soluble 
84 
 
MS 
95 % 
1.525-1.531 
1.062-1.068 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
15.107 
 
Thiophene-2-carbaldehyde 
S
O  
11874 
98-03-3 
Liquid 
C5H4OS 
112.15 
Slightly soluble 
Freely soluble 
198 
 
MS 
95 % 
1.585-1.592 
1.216-1.225 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.108 
 
2-Thiophenemethanethiol S
SH
 
 
 
6258-63-5 
Liquid 
C5H6S2 
130.22 
Slightly soluble 
Freely soluble 
82 (16 hPa) 
 
MS 
95 % 
1.571-1.578 
1.165-1.171 
 
 
15.114 
 
5-Acetyl-2,3-dihydro-1,4-thiazine 
N
H
S
O 4296 
 
101417-25-8 
Solid 
C6H9NOS 
143.2 
Sparringly soluble 
Freely soluble 
242 
126 
NMR 
95 % 
n.a. 
n.a. 
Register name to be 
changed to 6-Acetyl-2,3-
dihydro-1,4-thiazine.  
Substance not supported 
by Industry (EFFA, 
2009c). 
15.115 
 
2-Isobutyl-4-methyl thiazole 
N
S  
 
61323-24-8 
Solid 
C8H13NS 
155.26 
Slightly soluble 
Freely soluble 
189 
88 
MS 
95 % 
n.a. 
n.a. 
Register name to be 
changed to 2-Isobutyl-4-
methylthiazole. 
15.116 
 
2-Acetyl-4-ethylthiazole 
N
S
O  
 
233665-91-3 
Solid 
C7H9NOS 
155.22 
Slightly soluble 
Freely soluble 
270 
142 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.118 
 
4-Butylthiazole 
N
S  
 
53833-33-3 
Solid 
C7H11NS 
141.23 
Practically insoluble or 
insoluble 
Freely soluble 
212 
79 
MS 
95 % 
n.a. 
n.a. 
 
 
15.119 
 
2-Isobutyl-3-thiazoline 
N
S
 
 
 
39800-92-5 
Solid 
C7H13NS 
143.25 
Very slightly soluble 
Freely soluble 
197 
80 
MS 
95 % 
n.a. 
n.a. 
Racemate (EFFA, 2011f). 
15.129 
 
Tetrahydro-2,4,6-trimethyl-
1,3,5(2H)-thiadiazine 
HN NH
S  
 
53897-63-5 
Solid 
C6H14N2S 
146 
Soluble 
Soluble 
216-266 (1 hPa) 
65-70 
 
99 % 
n.a. 
n.a. 
ID 7). 
Mixture of 
diastereoisomers (EFFA, 
2010a). Mixture of 
isomers ((R/R), (R/S), 
(S/R) & (S/S) at equal 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
ratio, i.e. 25 % of each) 
(EFFA, 2011f). Substance 
not supported by Industry 
(EFFA, 2009c). 
15.133 
 
5-Acetyl-2,3-dihydro-1,4-thiazine S
N
H
O
 
 
164524-93-0 
Solid 
C6H9NOS 
143 
Soluble 
Soluble 
289+/-30 
67-69 
 
98% 
n.a. 
n.a. 
ID 7). 
Substance not supported 
by Industry (EFFA, 
2009c). 
15.135 
 
Ethyl thialdine   
S
N
H
S
 
4667 
 
54717-14-5 
Liquid 
C7H15NS2 
177.33 
Poorly soluble 
Soluble 
75 
 
IR NMR MS 
90 % 
1.5344-1.5544 
1.0745-1-0765 
CASrn in Register does 
not specify stereoisomeric 
composition. Min assay 
value 90 %. Remaining 
impurities: 3,5-diethyl-
1,2,4-trithiolane (<5 %) , 
thialdine (<2 %), other 
impurities (<3 %) 
(Flavour Industry, 2011f). 
Composition of 
stereoisomeric mixture to 
be specified. 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
7) ID: Missing identification test. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON THE MSDI APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.037 
 
2-Acetyl-3-methylthiophene 
S
O 0.18 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.038 
 
2-Acetyl-4-methylthiazole 
N
S
O 0.0049 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.039 
 
2-Acetyl-5-methylthiazole 
N
S
O 0.0024 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.040 
 
2-Acetylthiophene 
S
O 2.2 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.043 
 
2-Butyl-5-ethylthiophene S 0.0012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.044 
 
2-Butylthiazole 
N
S 0.011 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.045 
 
2-Butylthiophene S 0.012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.050 
 
2,5-Diethyl-4-methylthiazole 
N
S 0.012 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.051 
 
2,5-Diethyl-4-propylthiazole 
N
S 0.0012 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.052 
 
2,5-Diethylthiazole 
N
S 0.015 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.054 
 
Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine 
S NH
S 0.0012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.058 
 
4,5-Dimethyl-2-ethylthiazole 
N
S 0.015 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.061 
 
2,5-Dimethyl-4-ethylthiazole 
N
S 0.011 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.062 
 
2,4-Dimethylthiazole 
N
S 0.61 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.063 
 
2,5-Dimethylthiazole 
N
S 0.0061 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.064 
 
2,5-Dimethylthiophene S 0.23 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.067 
 
4-Ethyl-2-methylthiazole 
N
S 0.0037 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.068 
 
5-Ethyl-2-methylthiazole 
N
S 0.0061 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.069 
 
4-Ethyl-5-methylthiazole 
N
S 0.012 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.070 
 
2-Ethyl-5-methylthiophene S 0.061 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.071 
 
2-Ethylthiazole 
N
S 0.028 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.072 
 
2-Ethylthiophene S 0.0012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.074 
 
5-Ethylthiophene-2-
carbaldehyde 
S
O 0.0012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.076 
 
2-Hexylthiophene S 0.12 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.078 
 
2-Isobutyl-4,5-dimethylthiazole 
N
S 0.12 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.080 
 
2-Isopropyl-4,5-dimethylthiazole 
N
S
0.012 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.084 
 
5-Methyl-2-pentylthiazole 
N
S 0.0037 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.085 
 
4-Methyl-2-propionylthiazole 
N
S
O 0.0037 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.089 
 
2-Methylthiazole 
N
S 0.018 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.091 
 
2-Methylthiophene S 0.019 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.092 
 
3-Methylthiophene S
 
0.12 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.093 
 
2-Octylthiophene S 0.012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.094 
 
2-Pentanoylthiophene 
S
O 0.0012 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.096 
 
sec-Pentylthiophene S 0.24 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.097 
 
2-Propionylthiophene 
S
O 0.12 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.098 
 
2-Propylthiazole 
N
S 0.085 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
FGE.21Rev3
 
 
42 EFSA Journal 2012; 10(2):2457 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.107 
 
Thiophene-2-carbaldehyde 
S
O 0.21 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.115 
 
2-Isobutyl-4-methyl thiazole 
N
S 0.011 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.116 
 
2-Acetyl-4-ethylthiazole 
N
S
O 0.024 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.118 
 
4-Butylthiazole 
N
S 1.3 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.129 
 
Tetrahydro-2,4,6-trimethyl-
1,3,5(2H)-thiadiazine 
HN NH
S 0.61 
 
Class II 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.060 
 
2,4-Dimethyl-3-thiazoline 
N
S 0.012 
 
Class II 
No evaluation 
  b) 
15.086 
 
2-Methyl-2-thiazoline 
N
S 0.24 
 
Class II 
No evaluation 
  b) 
15.090 
 
2-Methylthiazolidine 
NH
S 0.024 
 
Class II 
No evaluation 
  c) 
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.099 
 
2-Propylthiazolidine 
NH
S 0.012 
 
Class II 
No evaluation 
  c) 
15.119 
 
2-Isobutyl-3-thiazoline 
N
S 0.011 
 
Class II 
No evaluation 
  b) 
15.042 
 
2-Butyl-4-
methyl(4H)pyrrolidino[1,2d]-
1,3,5-dithiazine 
S N
S 0.0012 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.055 
 
2,4-
Dimethyl(4H)pyrrolidino[1,2e]-
1,3,5-dithiazine 
S N
S
0.055 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.057 
  
4,6-Dimethyl-2-(1-
methylethyl)dihydro-1,3,5-
dithiazine 
S
N
H
S
1.5 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.077 
 
4-Hydroxy-2,5-
dimethylthiophen-3(2H)-one 
S
HO O
0.12 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.079 
 
2-Isobutyldihydro-4,6-dimethyl-
1,3,5-dithiazine 
S
N
H
S
5.7 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.082 
 
3-Mercaptothiophene S
SH
0.011 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
15.087 
 
2-Methyl-3-mercaptothiophene S
SH
0.12 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.088 
 
2-Methyl-4,5-benzothiazole 
N
S 0.0085 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.106 
 
Thiophene S
 
0.12 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.108 
 
2-Thiophenemethanethiol S
SH
0.0073 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
15.135 
 
Ethyl thialdine 
S
N
H
S
0.61 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required   
15.114 
 
5-Acetyl-2,3-dihydro-1,4-
thiazine 
N
H
S
O 0.012 
 
Class III 
No evaluation 
  c) 
15.133 
 
5-Acetyl-2,3-dihydro-1,4-
thiazine 
S
N
H
O
0.61 
 
Class III 
No evaluation 
  c) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
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8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Substance not supported by Industry (EFFA, 2009c). 
b) Genotoxic potential in vitro. 
c) Genotoxic potential in vitro. Substance not supported by Industry (EFFA, 2009c). 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
 2-Isobutyl-4,6-
dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-2,6-
dimethyldihydro-1,3,5-
dithiazine (mixture) 
S
N
H
S S
N
H
S
(Mixture)
3781 
 
101517-87-7 and 
101517-86-6 
1046 
JECFA specification 
(JECFA, 2002d) 
0.1  
No safety concern a) 
Not in EU-Register. 
 2-Isopropyl-4,6-dimethyl 2,6-
dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-2,6-
dimethyldihydro-1,3,5-
dithiazine (mixture) 
S
N
H
S S
N
H
S
(Mixture)
3782 
 
104691-41-0 and 
104691-40-9 
1047 
JECFA specification 
(JECFA, 2002d) 
ND  
No safety concern a) 
Not in EU-Register. 
15.001 2-Mercaptothiophene S SH 3062 
478 
7774-74-5 
1052 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern a) 
Deleted b) 
JECFA evaluated 2-thienyl 
mercaptan (CASrn as in 
Register). 
15.002 2-Methyl-5-methoxythiazole 
N
SO 3192 
736 
38205-64-0 
1057 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern a) 
Category B b) 
 
15.004 5-Methyl-2-
thiophenecarbaldehyde 
S
O 3209 
2203 
13679-70-4 
1050 
JECFA specification 
(JECFA, 2002d) 
0.73  
No safety concern a) 
Deleted b) 
 
15.005 2,4-Dimethyl-5-vinylthiazole 
N
S 3145 
2237 
65505-18-2 
1039 
JECFA specification 
(JECFA, 2002d) 
ND  
No safety concern a) 
Category B b) 
 
15.008 2-Thienyl disulfide 
S S
S
S 3323 
2333 
6911-51-9 
1053 
JECFA specification 
(JECFA, 2002d) 
0.061  
No safety concern a) 
Category B b) 
 
15.011 5-Acetyl-2,4-dimethylthiazole 
N
S
O 3267 
2336 
38205-60-6 
1055 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern a) 
Category B b) 
JECFA evaluated 2,4-dimethyl-5-
acetylthiazole (CASrn as in 
Register). 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
15.013 2-Isobutylthiazole 
N
S 3134 
11618 
18640-74-9 
1034 
JECFA specification 
(JECFA, 2002d) 
2.3  
No safety concern a) 
 
 
15.014 5-(2-Hydroxyethyl)-4-
methylthiazole 
N
SHO 3204 
11621 
137-00-8 
1031 
JECFA specification 
(JECFA, 2002d) 
150  
No safety concern a) 
 
 
15.015 4-Methyl-5-(2-
acetoxyethyl)thiazole 
N
SO
O
3205 
11620 
656-53-1 
1054 
JECFA specification 
(JECFA, 2002d) 
8.6  
No safety concern a) 
 
JECFA evaluated 4-methyl-5-
thiazoleethanol acetate (CASrn 
as in Register). 
15.016 Benzothiazole 
N
S 3256 
11594 
95-16-9 
1040 
JECFA specification 
(JECFA, 2002d) 
1.2  
No safety concern a) 
 
 
15.017 4,5-Dimethylthiazole 
N
S 3274 
11606 
3581-91-7 
1035 
JECFA specification 
(JECFA, 2002d) 
0.18  
No safety concern a) 
 
 
15.018 4-Methyl-5-vinylthiazole 
N
S 3313 
11633 
1759-28-0 
1038 
JECFA specification 
(JECFA, 2002d) 
2.1  
No safety concern a) 
 
 
15.019 2,4,5-Trimethylthiazole 
N
S 3325 
11650 
13623-11-5 
1036 
JECFA specification 
(JECFA, 2002d) 
0.61  
No safety concern a) 
 
 
15.020 2-Acetylthiazole 
N
S
O 3328 
11726 
24295-03-2 
1041 
JECFA specification 
(JECFA, 2002d) 
9.7  
No safety concern a) 
 
 
15.021 2-Ethoxythiazole 
N
S O 3340 
11611 
15679-19-3 
1056 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern a) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
15.022 2-(sec-Butyl)thiazole 
N
S
3372 
11598 
18277-27-5 
1033 
JECFA specification 
(JECFA, 2002d) 
0.024  
No safety concern a) 
 
JECFA evaluated 2-(1-
methylpropyl)thiazole (CASrn as 
in Register). (R)- or (S)- 
enantiomer not specified by 
CASrn in Register. 
15.024 3-Acetyl-2,5-
dimethylthiophene 
S
O
3527 
11603 
2530-10-1 
1051 
JECFA specification 
(JECFA, 2002d) 
18  
No safety concern a) 
 
 
15.026 2-Isopropyl-4-methylthiazole 
N
S
3555 
 
15679-13-7 
1037 
JECFA specification 
(JECFA, 2002d) 
19  
No safety concern a) 
 
 
15.027 2-Propionylthiazole 
N
S
O 3611 
 
43039-98-1 
1042 
JECFA specification 
(JECFA, 2002d) 
0.056  
No safety concern a) 
 
 
15.029 2-(sec-Butyl)-4,5-dimethyl-3-
thiazoline 
N
S
3619 
 
65894-82-8 
1059 
JECFA specification 
(JECFA, 2002d) 
ND  
No safety concern a) 
 
JECFA evaluated 2-(2-Butyl)-
4,5-dimethyl-3-thiazoline 
(CASrn as in Register). (R)- or 
(S)- enantiomer not specified by 
CASrn in Register. 
15.030 4,5-Dimethyl-2-ethyl-3-
thiazoline 
N
S 3620 
 
76788-46-0 
1058 
JECFA specification 
(JECFA, 2002d) 
ND  
No safety concern a) 
 
JECFA evaluated 4,5-dimethyl-2-
ethyl-3-thiazoline (CASrn as in 
Register). (R)- or (S)- enantiomer 
not specified by CASrn in 
Register. 
15.032 4,5-Dimethyl-2-isobutyl-3-
thiazoline 
N
S 3621 
 
65894-83-9 
1045 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern a) 
 
JECFA evaluated 4,5-dimethyl-2-
isobutyl-3-thiazoline (CASrn as 
in Register). (R)- or (S)- 
enantiomer not specified by 
CASrn in Register. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
15.033 2-Ethyl 4-methylthiazole 
N
S 3680 
11612 
15679-12-6 
1044 
JECFA specification 
(JECFA, 2002d) 
3.2  
No safety concern a) 
 
 
15.035 4-Methylthiazole 
N
S
 
3716 
11627 
693-95-8 
1043 
JECFA specification 
(JECFA, 2002d) 
0.097  
No safety concern a) 
 
 
15.109 2,4,6-Trimethyldihydro-
1,3,5(4H)-dithiazine 
S NH
S 4018 
11649 
638-17-5 
1049 
JECFA specification 
(JECFA, 2002d) 
ND  
No safety concern a) 
 
JECFA evaluated 2,4,6-
trimethyldihydro-4H-1,3,5-
dithiazine (CASrn as in 
Register). (R)- or (S)- enantiomer 
not specified by CASrn in 
Register. 
15.113 5,6-Dihydro-2,4,6,tris(2-
methylpropyl)4H-1,3,5-
dithiazine 
S NH
S
4017 
 
74595-94-1 
1048 
JECFA specification 
(JECFA, 2002d) 
ND  
No safety concern a) 
 
JECFA evaluated 2,4,6-
triisobutyl-5,6-dihydro-4H-1,3,5-
dithiazine (CASrn as in 
Register). (R)- or (S)- enantiomer 
not specified by CASrn in 
Register. 
16.027 Thiamine hydrochloride 
+NH3
N+
S
N
N
HO
2 Cl-
3322 
10493 
67-03-8 
1030 
JECFA specification 
(JECFA, 2002d) 
300  
No safety concern a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs; Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2002c). 
b) (CoE, 1992). 
ND) No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a; Flavour Industry, 2004-5). 
According to the Industry the ”normal use” is defined as the average of reported usages and ”maximum use” 
is defined as the 95th percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring substances 
(EFFA, 2002i). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
The “normal and maximum use levels” are provided by Industry for 57 candidate substances in the present 
flavouring group (Table II.1.2). 
Table II.1.2. Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.21Rev3 (EFFA, 
2004g; EFFA, 2004i; EFFA, 2007a; Flavour Industry, 2004-5; Flavour Industry, 2010j). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
15.037 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.038 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.039 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
- 
- 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.040 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.042 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.043 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.044 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.045 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.050 0,4 0,2 0,4 0,3 - 0,4 0,2 0,4 0,1 0,1 - - 0,2 0,4 0,2 0,4 1 0,2 
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Table II.1.2. Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.21Rev3 (EFFA, 
2004g; EFFA, 2004i; EFFA, 2007a; Flavour Industry, 2004-5; Flavour Industry, 2010j). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
2 1 2 1,5 - 2 1 2 0,4 0,4 - - 1 2 1 2 5 1 
15.051 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.052 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.054 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.055 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
0,4 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.058 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,1 
0,5 
0,4 
2 
1 
5 
0,2 
1 
15.060 0,4 
2 
0,2 
1 
0,2 
1 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.061 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.062 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
0,4 
2 
- 
- 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
- 
- 
1 
5 
0,2 
1 
15.063 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.064 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.067 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.068 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
1 
5 
0,2 
1 
0,4 
2 
- 
- 
0,2 
1 
15.069 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.070 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.071 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.072 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.074 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.076 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.077 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.078 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.080 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.082 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.084 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.085 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.086 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.087 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.088 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.089 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
- 
- 
0,4 
2 
0,2 
1 
0,2 
1 
1 
5 
0,2 
1 
15.090 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.091 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.092 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.093 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
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Table II.1.2. Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.21Rev3 (EFFA, 
2004g; EFFA, 2004i; EFFA, 2007a; Flavour Industry, 2004-5; Flavour Industry, 2010j). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
15.094 0,4 
2 
0,2 
1 
- 
- 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.096 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.097 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.098 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.099 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.106 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.107 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.108 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,2 
1 
15.114 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.115 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.116 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.118 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.119 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.129 0,1 
2,5 
0,1 
2,5 
1 
25 
0,1 
2,5 
0,1 
2,5 
10 
250 
2 
50 
1 
25 
0,1 
2,5 
0,1 
2,5 
- 
- 
- 
- 
0,1 
2,5 
- 
- 
10 
250 
10 
250 
0,1 
2,5 
0,1 
2,5 
15.133 0,1 
0,5 
0,1 
0,5 
1 
5 
0,1 
0,5 
0,1 
0,5 
10 
50 
2 
10 
1 
5 
0,1 
0,5 
0,1 
0,5 
- 
- 
- 
- 
0,1 
0,5 
- 
- 
10 
50 
10 
50 
0,1 
0,5 
0,1 
0,5 
15.135 1,5 
3 
1 
2 
- 
- 
0,5 
1 
0,5 
1 
- 
- 
0,5 
1 
1,5 
3 
1,5 
3 
- 
- 
- 
- 
- 
- 
2 
12 
- 
- 
- 
- 
- 
- 
0,5 
1 
- 
- 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
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Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for 57 candidate substances in the present flavouring 
group, for which Industry has provided use and use levels (EFFA, 2004g; EFFA, 2004i; EFFA, 2007a; 
Flavour Industry, 2004-5; Flavour Industry, 2010j). The mTAMDI values are only given for the highest 
reported normal use levels (see Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
15.037 2-Acetyl-3-methylthiophene 78 Class II 540 
15.038 2-Acetyl-4-methylthiazole 160 Class II 540 
15.039 2-Acetyl-5-methylthiazole 160 Class II 540 
15.040 2-Acetylthiophene 78 Class II 540 
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TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
15.043 2-Butyl-5-ethylthiophene 78 Class II 540 
15.044 2-Butylthiazole 160 Class II 540 
15.045 2-Butylthiophene 78 Class II 540 
15.050 2,5-Diethyl-4-methylthiazole 160 Class II 540 
15.051 2,5-Diethyl-4-propylthiazole 160 Class II 540 
15.052 2,5-Diethylthiazole 160 Class II 540 
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 160 Class II 540 
15.058 4,5-Dimethyl-2-ethylthiazole 130 Class II 540 
15.061 2,5-Dimethyl-4-ethylthiazole 160 Class II 540 
15.062 2,4-Dimethylthiazole 140 Class II 540 
15.063 2,5-Dimethylthiazole 160 Class II 540 
15.064 2,5-Dimethylthiophene 78 Class II 540 
15.067 4-Ethyl-2-methylthiazole 160 Class II 540 
15.068 5-Ethyl-2-methylthiazole 220 Class II 540 
15.069 4-Ethyl-5-methylthiazole 160 Class II 540 
15.070 2-Ethyl-5-methylthiophene 78 Class II 540 
15.071 2-Ethylthiazole 160 Class II 540 
15.072 2-Ethylthiophene 78 Class II 540 
15.074 5-Ethylthiophene-2-carbaldehyde 78 Class II 540 
15.076 2-Hexylthiophene 78 Class II 540 
15.078 2-Isobutyl-4,5-dimethylthiazole 160 Class II 540 
15.080 2-Isopropyl-4,5-dimethylthiazole 160 Class II 540 
15.084 5-Methyl-2-pentylthiazole 160 Class II 540 
15.085 4-Methyl-2-propionylthiazole 160 Class II 540 
15.089 2-Methylthiazole 150 Class II 540 
15.091 2-Methylthiophene 78 Class II 540 
15.092 3-Methylthiophene 78 Class II 540 
15.093 2-Octylthiophene 160 Class II 540 
15.094 2-Pentanoylthiophene 160 Class II 540 
15.096 sec-Pentylthiophene 160 Class II 540 
15.097 2-Propionylthiophene 160 Class II 540 
15.098 2-Propylthiazole 160 Class II 540 
15.107 Thiophene-2-carbaldehyde 78 Class II 540 
15.115 2-Isobutyl-4-methyl thiazole 160 Class II 540 
15.116 2-Acetyl-4-ethylthiazole 160 Class II 540 
15.118 4-Butylthiazole 160 Class II 540 
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 4000 Class II 540 
15.060 2,4-Dimethyl-3-thiazoline 160 Class II 540 
15.086 2-Methyl-2-thiazoline 160 Class II 540 
15.090 2-Methylthiazolidine 160 Class II 540 
15.099 2-Propylthiazolidine 160 Class II 540 
15.119 2-Isobutyl-3-thiazoline 160 Class II 540 
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine 160 Class III 90 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 160 Class III 90 
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine  Class III 90 
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one 78 Class III 90 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine  Class III 90 
15.082 3-Mercaptothiophene 78 Class III 90 
15.087 2-Methyl-3-mercaptothiophene 78 Class III 90 
15.088 2-Methyl-4,5-benzothiazole 160 Class III 90 
15.106 Thiophene 78 Class III 90 
15.108 2-Thiophenemethanethiol 78 Class III 90 
15.135 Ethyl thialdine 250 Class III 90 
15.114 5-Acetyl-2,3-dihydro-1,4-thiazine 160 Class III 90 
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine 4000 Class III 90 
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ANNEX III: METABOLISM  
III.1. Introduction 
The candidate substances in this FGE are structurally related to the 29 flavouring substances evaluated in 
“Safety Evaluations of Groups of Related Flavouring Agents: Sulfur-Containing Heterocyclic Compounds” 
(JECFA, 2002c). 
The candidate substances from EU chemical groups 29 and 30 in this FGE include five- and six-membered 
sulphur-containing aromatic and non-aromatic heterocycles, which have been arranged into 9 subgroups in 
order to facilitate comparisons of the data sets between the groups. This division was done on the basis of 
degree of aromaticity and according to the presence of other heteroatoms (i.e. nitrogen). Subgroup A-I has 
been further divided into three subgroups: A-Ia (thiophene), A-Ib (thiophenes with alkyl, acyl or 
carbaldehyde ring substituents) and A-Ic (thiophenes with thiol-containing ring substituents). So, in total 11 
subgroups. 
The substances and subgroups are presented in Table III.1: 
Table III.1 Division of candidate and supporting substances into structurally related subgroups – supporting 
substances are listed in brackets 
FL-no EU Register name Structural formula 
A-Ia: Thiophene: 
15.106 Thiophene S
A-Ib: Thiophenes (with non-thiol-containing ring substituents): 
(15.004) (5-Methyl-2-thiophenecarbaldehyde) 
S
O
 
(15.024) (3-Acetyl-2,5-dimethylthiophene) S
O
 
15.037 2-Acetyl-3-methylthiophene 
S
O
 
15.040 2-Acetylthiophene 
S
O
 
15.043 2-Butyl-5-ethylthiophene S
 
15.045 2-Butylthiophene S
 
15.064 2,5-Dimethylthiophene S
 
15.070 2-Ethyl-5-methylthiophene S
 
15.072 2-Ethylthiophene S
 
15.074 5-Ethylthiophene-2-carbaldehyde 
S
O
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Table III.1 Division of candidate and supporting substances into structurally related subgroups – supporting 
substances are listed in brackets 
FL-no EU Register name Structural formula 
15.076 2-Hexylthiophene S
 
15.091 2-Methylthiophene S
 
15.092 3-Methylthiophene S
 
15.093 2-Octylthiophene S
 
15.094 2-Pentanoylthiophene 
S
O
 
15.096 2-Pentylthiophene (Register name: sec-Pentylthiophene)  S
 
15.097 2-Propionylthiophene 
S
O
 
15.107 Thiophene-2-carbaldehyde 
S
O
 
A-Ic: Thiophenes (with thiol-containing ring substituents): 
(15.001) (2-Mercaptothiophene) S SH
 
(15.008) (2-Thienyl disulfide) 
S S
S
S
 
15.082 3-Mercaptothiophene S
SH  
15.087 2-Methyl-3-mercaptothiophene S
SH  
15.108 2-Thiophenemethanethiol S SH
 
A-II: Thiazoles: 
(15.002) (2-Methyl-5-methoxythiazole) 
N
SO
 
(15.005) (2,4-Dimethyl-5-vinylthiazole) 
N
S
 
(15.011) (5-Acetyl-2,4-dimethylthiazole) 
N
S
O
 
(15.013) (2-Isobutylthiazole) 
N
S
 
(15.014) (5-(2-Hydroxyethyl)-4-methylthiazole) 
N
SHO
 
(15.015) (4-Methyl-5-(2-acetoxyethyl)thiazole) 
N
SO
O
 
(15.017) (4,5-Dimethylthiazole) 
N
S
 
(15.018) (4-Methyl-5-vinylthiazole) 
N
S
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Table III.1 Division of candidate and supporting substances into structurally related subgroups – supporting 
substances are listed in brackets 
FL-no EU Register name Structural formula 
(15.019) (2,4,5-Trimethylthiazole) 
N
S
 
(15.020) (2-Acetylthiazole) 
N
S
O
 
(15.021) (2-Ethoxythiazole) 
N
S O
 
(15.022) (2-(sec-Butyl)thiazole) 
N
S
 
(15.026) (2-Isopropyl-4-methylthiazole) 
N
S
 
(15.027) (2-Propionylthiazole) 
N
S
O
 
(15.033) (2-Ethyl 4-methylthiazole) 
N
S
 
(15.035) (4-Methylthiazole) 
N
S
 
15.038 2-Acetyl-4-methylthiazole 
N
S
O
 
15.039 2-Acetyl-5-methylthiazole 
N
S
O
 
15.044 2-Butylthiazole 
N
S
 
15.050 2,5-Diethyl-4-methylthiazole 
N
S
 
15.051 2,5-Diethyl-4-propylthiazole 
N
S
 
15.052 2,5-Diethylthiazole 
N
S
 
15.058 4,5-Dimethyl-2-ethylthiazole 
N
S
 
15.061 2,5-Dimethyl-4-ethylthiazole 
N
S
 
15.062 2,4-Dimethylthiazole 
N
S
 
15.063 2,5-Dimethylthiazole 
N
S
 
15.067 4-Ethyl-2-methylthiazole 
N
S
 
15.068 5-Ethyl-2-methylthiazole 
N
S
 
15.069 4-Ethyl-5-methylthiazole 
N
S
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Table III.1 Division of candidate and supporting substances into structurally related subgroups – supporting 
substances are listed in brackets 
FL-no EU Register name Structural formula 
15.071 2-Ethylthiazole 
N
S
 
15.078 2-Isobutyl-4,5-dimethylthiazole 
N
S
 
15.080 2-Isopropyl-4,5-dimethylthiazole 
N
S
 
15.084 5-Methyl-2-pentylthiazole 
N
S
 
15.085 4-Methyl-2-propionylthiazole 
N
S
O
 
15.089 2-Methylthiazole 
N
S
 
15.098 2-Propylthiazole 
N
S
 
15.115 2-Isobutyl-4-methylthiazole 
N
S
 
15.116 2-Acetyl-4-ethylthiazole 
N
S
O
 
15.118 4-Butylthiazole 
N
S
 
(16.027) (Thiamine hydrochloride) 
H2N
N+
S
N
N
Cl-
HO
A-III: Benzothiazoles: 
(15.016) (Benzothiazole) 
N
S
 
15.088 2-Methyl-4,5-benzothiazole 
N
S
 
B-I : Dihydrothiophenes: 
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one S
HO O  
B-II: Thiazolines: 
(15.029) (2-(sec-Butyl)-4,5-dimethyl-3-thiazoline) 
N
S
 
(15.030) (4,5-Dimethyl-2-ethyl-3-thiazoline) 
N
S
 
(15.032) (4,5-Dimethyl-2-isobutyl-3-thiazoline) 
N
S
 
15.060 2,4-Dimethyl-3-thiazoline 
N
S
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Table III.1 Division of candidate and supporting substances into structurally related subgroups – supporting 
substances are listed in brackets 
FL-no EU Register name Structural formula 
15.086 2-Methyl-2-thiazoline 
N
S
 
15.119 2-Isobutyl-3-thiazoline 
N
S
 
B-III: Thiazolidines: 
15.090 2-Methylthiazolidine 
NH
S
 
15.099 2-Propylthiazolidine 
NH
S
 
B-IV: Dithiazines: 
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine 
S N
S
 
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 
S NH
S
 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 
S N
S
 
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine 
S
N
H
S
 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 
S
N
H
S
 
(15.109) (2,4,6-Trimethyldihydro-1,3,5(4H)-dithiazine) 
S NH
S
 
(15.113) (5,6-Dihydro-2,4,6,tris(2-methylpropyl)4H-1,3,5-dithiazine) 
S NH
S
 
15.135 Ethyl thialdine 
S
N
H
S
 
(Not in EU Register) (2-Isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-
isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine (mixture)) 
S NH
S
S NH
S
(Mixture)
(Not in EU Register) (2-Isopropyl-4,6-dimethyl 2,6-dimethyldihydro-1,3,5-dithiazine 
and 4-isopropyl-2,6-dimethyldihydro-1,3,5-dithiazine 
(mixture)) 
S NH
S
S NH
S
(Mixture)
B-V: Dihydrothiazines: 
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Table III.1 Division of candidate and supporting substances into structurally related subgroups – supporting 
substances are listed in brackets 
FL-no EU Register name Structural formula 
15.114 6-Acetyl-2,3-dihydro-1,4-thiazine  
(Register name: 5-acetyl-2,3-dihydro-1,4-thiazine) 
N
H
S
O
 
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine S
N
H
O  
B-VI: Thiadiazines: 
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 
HN NH
S
 
The following is a description of the characteristic features of the 9 subgroups: 
A: Aromatic group: 
Subgroup A-I: Thiophenes (20 candidate substances and four supporting substances): aromatic heterocyclic 
five-membered ring substances with a sulphur atom at ring position 1. This group is further divided into 
three subgroups: A-Ia with thiophene, A-Ib with 16 ring-substituted thiophenes which have one or more 
alkyl, acyl or carbaldehyde substituents to the ring and subgroup A-Ic with three ring-substituted thiophenes 
which have a free thiol group in their ring-substituent group. 
Subgroup A-II: Thiazoles (23 candidate substances and 17 supporting substances): five-membered 
aromatic heterocycles containing one sulphur and one nitrogen atom in the 1- and 3-ring positions, 
respectively. To this heterocyclic ring one or more alkyl- or acyl- substituents may be attached. 
Subgroup A-III: Benzothiazoles (one candidate substance and one supporting substance): a bicyclic 
molecule consisting of a five-membered aromatic heterocycle, containing one sulphur and one nitrogen atom 
in the 1- and 3-ring positions, respectively, with a fused benzene ring at the 4- and 5-ring positions.  
B: Non-aromatic group: 
Subgroup B-I: Dihydrothiophenes (one candidate substance and no supporting substances): heterocyclic 
five-membered ring substance with a sulphur atom at ring position 1. Only one double bond is present in the 
ring. The ring bears several substituents.  
Subgroup B-II: Thiazolines (three candidate substances and three supporting substances): five-membered 
heterocycles containing a sulphur and a nitrogen atom in the 1- and 3-ring positions, respectively. In the ring, 
one double bond is present (in contrast to the thiazoles, which have two double bonds).  
Subgroup B-III: Thiazolidines (two candidate substances and no supporting substances): five-membered 
heterocycles containing a sulphur and a nitrogen atom in the 1- and 3-ring positions, respectively. In the ring 
no double bonds are present (cf. thiazoles and thiazolines). 
Subgroup B-IV: Dithiazines (six candidate substances and two supporting and two structurally related 
substances): six-membered non-aromatic heterocycles containing two sulphur atoms, and one nitrogen atom, 
with various ring substituents, including a fused second ring in two of these.  
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Subgroup B-V: Dihydrothiazines (two candidate substances and no supporting substances): a six-
membered heterocyclic ring, containing a sulphur and a nitrogen atom in para positions, and one double 
bond. The ring bears an acetyl substituent group.  
Subgroup B-VI: Thiadiazines (one candidate substance and no supporting substances): six-membered non-
aromatic heterocycles containing one sulphur atoms, and two nitrogen atoms in para-positions, with three 
methyl substituent groups.  
III.2. Absorption, Distribution and Elimination 
Only limited data were submitted for the evaluation of the absorption, distribution and elimination of the 
candidate flavouring substances in this group. The only candidate substance for which absorption and 
elimination were studied is thiophene [FL-no: 15.106]. Data were also submitted for a few more or less 
related substances. Because the information is so fragmentary, it is not useful to present it (sub)group-wise. 
In addition, some of the studies are related to oral exposure and some others to parenteral dosing, and the 
relevance of the latter may be limited.  
Candidate substances 
Thiophene [FL-no: 15.106] 
Single doses of 33 mg/kg bw [2,5-14C]-thiophene were administered to mice via oral and rectal intubation. At 
48 hours after the oral gavage dose, 78 % of the radioactivity was found in the urine, while 5 % was found in 
both faeces and expired air. At 24 hours after the rectal dose, 43 % was found in the urine, but 40 % was 
found in the expired air. The difference in the elimination pattern after oral vs. rectal administration was 
attributed to an extensive first-pass effect after the oral dose. Also, the oral dose resulted in 10 times higher 
levels of radioactivity in the liver as compared to the rectal dose. With thin-layer chromatography two 
urinary metabolites were observed. However, none of these metabolites and none of the radioactivity in 
tissues or excreta were further identified (Chanal et al., 1974). 
Female rats (200 - 250 g) and rabbits (2 - 3 kg) were administered thiophene as single oral gavage doses of 
60 mg and 450 mg, respectively. Urine was collected over a 24-hours period following dosing. Table III.2 
provides a summary of the quantitative determinations of metabolites in this study. 
Table III.2 Summary of excretion of metabolites of thiophene in rabbits and rats 
Metabolites Rabbit (N=6) Rat (N=3) 
(Pre)-mercapturic acids in urine 38 (32 – 49) 40 (36 – 45) 
Free thiophene expired Not determined 32 (29 – 35) 
Free thiophene in faeces Not determined 0.48 (0.25 – 0.68) 
Tabulated data are percentage of administered dose (%) 
Other urinary metabolites, in particular conjugates of 2-hydroxy- or 3-hydroxythiophene, any acid-
hydrolysable products of thiophene or free thiophene were not found (Bray et al., 1971). 
When male Sprague-Dawley rats were injected intraperitoneally with a 200 mg/kg bw dose of tritiated (at C2 
and C5 positions) thiophene in corn oil, approximately 31 % of the radioactivity was excreted between 0 and 
15 hours, while 4 % of the radioactivity was excreted between 15 and 50 hours. More than 94 % of the 
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urinary radioactivity was accounted for by a single metabolite, the 2-mercapturic acid derivative of 1,4-
dihydrothiophene-S-oxide (Dansette et al., 1992). 
In rats, a single subcutaneous dose of 35S-thiophene was rapidly absorbed into the blood stream. Thiophene 
produced a peak blood concentration within 30 minutes and peak levels in the brain within three hours. 
Radioactivity was excreted in the urine at 61.1 % of the dose within 34 hours and 74.4 % of the dose within 
three days (Bikbulatov and Nigmatullina, 1976; O’Donoghue, 2000). 
Non-candidate substances: 
In two male Sprague-Dawley rats, approximately 20 % of the radioactivity of an intraperitoneal injection of 
30 mg/kg bw of the 3-aroylthiophene (tienilic acid isomer 1)10 (14C at the keto position) is recovered in the 
urine within 24 hours. Approximately 15 % of urinary radioactivity could be accounted for as a mixture of 
two diastereoisomers of the mercapturic acid conjugate of the 3-aroyl-4,5-dihydrothiophene. The study was 
designed to identify these two metabolites. The rest of the urinary radioactivity was identified as parent 
substance (ca. 17 % of the dose) and an unidentified metabolite (ca. 1 % of the dose), presumably a 
derivative of one or both of the already identified mercapturates (Valadon et al., 1996). 
When the benzothiazole derivative fostedil11 was administered to dogs via intravenous infusion or orally as 
solution, suspension or as encapsulated substance, mean relative bioavailabilities for the parent substance 
after oral dosing could be calculated to be 71, 64 or 42 %, respectively. The substance was cleared from the 
plasma with a terminal half-life of 6 - 9 hours and based on high biliary excretion, enterohepatic circulation 
has been suggested. When the substance was administered with a radiolabel (no further details) 80 % of the 
radioactivity was found in the faeces (Thomas, 1984; Thomas and Bopp, 1984).  
In a previous FGE.24Rev1 (EFSA, 2008t) data on the absorption and elimination of indole12 have been 
discussed. As this substance bears some resemblance to the benzothiazoles in subgroup A-III, these data are 
also briefly mentioned here. After oral dosing of 2-14C-indole to rats 62 - 82 % of the administered 
radioactivity was excreted via urine or expired air within 48 - 72 hours post-dosing. 
The substances in subgroup B-IV (the dithiazines with FL-no: 15.042, 15.054, 15.055, 15.057, 15.079 and 
15.135) may be regarded as cyclic thioacetals, which could be subject to acid hydrolysis in the stomach, 
similar to oxygen-containing acetals. However, thioacetals are more resistant to hydrolysis than oxygen 
acetals. In addition, chances of hydrolysis would be reduced even more by their cyclic character (Smith and 
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March, 2001; EFSA, 2011u). It is thus anticipated that these substances may be expected to reach the 
intestinal lumen intact and may also be absorbed as such. 
III.3. Metabolism 
In the sections below, the metabolism data available have been presented according to the division into 
subgroups of the candidate flavouring substances in this FGE. 
III.3.1. Aromatic candidate substances 
Subgroup A-Ia thiophene and A-Ib thiophenes with non-thiol-containing ring substituents 
(Candidate substances [FL-no: 15.037, 15.040, 15.043, 15.045, 15.064, 15.070, 15.072, 15.074, 15.076, 
15.091, 15.092, 15.093, 15.094, 15.096, 15.097, 15.106 and 15.107]) 
Candidate substances: 
Thiophene [FL-no: 15.106] 
Thiophene was administered to female rats (200 - 250 g) and rabbits (2 - 3 kg) as single oral gavage doses of 
60 mg and 450 mg, respectively. Urine was collected over a 24-hours period following dosing. The 
predominant metabolites excreted in the urine were a mercapturic acid and a premercapturic acid, which 
according to the study authors could result from the conjugation of glutathione with an intermediate 2,3-
thiophene-epoxide. 2-Thienylmercapturic acid was excreted in relatively small quantities and 3-hydroxy-2,3-
dihydro-2-thienyl-mercapturic acid was the major metabolite excreted in urine. The metabolites were 
identified by IR spectroscopy, GLC and MS techniques and further by characteristic chemical reactions of 
thiophene derivatives (desulphuration following treatment of the premercapturic acid with Raney nickel 
resulting in the formation of 2-butanol) (Bray et al., 1971). 
More recently, male Wistar rats (190 - 400 g) were injected intraperitoneally with 0.2 mmol (= ~ 17 mg) 
thiophene in peanut oil, and mercapturic acids were not found to be important thioethers (i.e. comprising not 
more than about 1 % of the dose) excreted in the urine (Hickman et al., 1992), contrary to the results of Bray 
et al (Bray et al., 1971). It is noted that 2-thienyl mercapturic acid was also identified as a less important 
metabolite by Bray et al. (1971) and that the two studies differ in route of administration. The oral route of 
administration (Bray et al., 1971) results in higher metabolic conversion as compared to the intraperitoneal 
one (Hickman et al., 1992). In addition, identification of thioethers by Hickman et al. (1992) was only done 
by reaction with Ellman’s reagent following extraction and hydrolysis of the urine samples. No attempts 
were made to identify any other thiophene metabolite in urine samples. 
When male Sprague-Dawley rats were injected (intraperitoneal) with 200 mg/kg bw [2,5-3H]-labelled 
thiophene, more than 94 % of the urinary radioactivity was accounted for by the 2-mercapturic acid 
derivative of 2,5-dihydrothiophene-S-oxide, as identified by NMR, IR and Mass spectroscopical techniques. 
A small second peak in the HPLC diagram of the urine radioactivity was also observed, but this peak was not 
further studied. The authors concluded that its formation occurred by S-oxidation yielding the very reactive 
thiophene sulphoxide, which undergoes Michael-type addition of glutathione at the 2-position. In subsequent 
reactions, the glutathione moiety of this metabolite is converted into an N-acetyl cysteine group. The final 
metabolite is subsequently excreted via urine, and may be converted spontaneously into 2-thienyl-
mercapturic acid (Dansette et al., 1992). The authors considered the formation of the epoxide intermediate, 
as suggested by Bray et al. (1971), highly unlikely.  
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Based on subsequent studies with chemically defined reaction mixtures and with microsomal incubations, the 
formation of the 2,5-dihydrothiophene-S-oxide was further substantiated by the formation of two 
diastereoisomeric thiophene S-oxide dimers (3a,4,7,7a-tetrahydro-4,7epithiobenzo[b]thiophene 1,8 dioxide) 
one of which (the 1-syn,-8-syn,endo-isomer) was suggested having been observed in the in vivo studies by 
Dansette et al (ca. 10 % of urinary radioactivity, comprising 2 % of the oral dose in the above study; the 
unidentified second peak (see above)). The formation of the dimers may result from a Diels−Alder reaction. 
Thus, the metabolic fate for the thiophene S-oxide in vivo involves predominantly reaction with nucleophiles 
such as glutathione (catalysed by glutathione S-transferase) leading eventually to mercapturate derivatives 
that are excreted in the urine, or to a lesser extent it involves dimerization and the resulting dimer is also 
excreted via the urine (Treiber et al., 1997). 
 
Non-candidate substances: 
In two male Sprague-Dawley rats injected i.p. with the 3-aroylthiophene tienilic acid isomer 1 (see above), 
15 % of urinary radioactivity (~ 2 % of the dose) could be accounted for as a mixture of two 
diastereoisomers of the mercapturic acid conjugate of 3-aroyl-4,5-dihydrothiophene. In the ultimate urinary 
metabolite, the N-acetylcysteine residue (mercapturate) is found in the 4-position of the thiophene ring. This 
residue may be introduced at that position after initial Michael-type addition of glutathione to the primary 
thiophene sulphoxide metabolite (see Figure III.1) at the ring position 2 (i.e. the C next to the S atom) and 
several rearrangements, including ring opening / closing and reaction with second GSH molecules. Results 
of in vitro experiments with rat liver microsomes indicate that the thiophene sulphoxide is a reactive 
intermediate in the conversion of the 3-aroylthiophene to the dihydromercapturic acid metabolite (Valadon et 
al., 1996). 
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Figure III.1. Proposed metabolism of 3-alkylthiophenes 
 
Oxidation of 2-phenylthiophene by rat liver microsomes, in the presence of NADPH and glutathione (GSH) 
involves two initial reactions, resulting in three subsequent types of metabolites. The first reaction involves 
S-oxidation to yield 2-phenylthiopene S-oxide that then dimerizes by Diels–Alder type reaction of the S-
oxide. Alternatively, the S-oxide alternatively may form a glutathione adduct via a 1,4-Michaël-type addition 
of glutathione to the C5 position of 2-phenylthiopene S-oxide. The second metabolic reaction involves 
formation of a 2-phenylthiophene-4,5-epoxide which may be subject to subsequent conjugation with 
FGE.21Rev3
 
 
67 EFSA Journal 2012; 10(2):2457 
glutathione at C4 of the thiophene ring. Subsequent dehydration of the resulting hydroxyl-glutathione 
conjugate yields the corresponding glutathione conjugate of phenylthiopene which is excreted mainly as the 
2-mercapturic derivative. Oxidation of 2-phenylthiophene by recombinant, human cytochrome P450 1A1, in 
the presence of NADPH and glutathione, also led to these metabolites. These results provide the evidence 
that cytochrome P450 (1A1) may catalyze the oxidation of thiophene compounds with the simultaneous 
formation of two reactive intermediates, a thiophene-S-oxide and a thiophene epoxide (Dansette et al., 2005). 
The addition of alkyl substituents can result in a significant change in metabolism. Biotransformation of a 
thiophene derivative was studied in six male healthy volunteers after administration of a single oral dose of 
12.5 mg olanzapine13. Mean radiocarbon recovery was 87 %, with 30 % appearing in the feces and 57 % 
excreted in the urine. In addition to other metabolites, the methyl substituent on the thiophene ring 
underwent oxidation to the corresponding 2-hydroxymethyl and 2-carboxylic acid derivatives. There was no 
evidence for glutathione conjugation of the thiophene S-oxide or epoxidation of the thiophene ring double 
bond for alkyl-substituted thiophenes (Kassahun et al., 1997). However, the total recovery and identification 
of metabolites in urine or faeces was far from complete and some metabolites may have been missed in the 
analysis. In addition, reactions alternative to S-oxidation (e.g. N-oxidation or n-glucuronidation) may greatly 
reduce the relevance of the S-oxidation in this substance as compared to more simple alkyl-substituted 
thiophenes. 
 
Subgroup A-Ic: Thiophenes with a thiol group in the ring substituent 
Candidate substances [FL-no: 15.082, 15.087 and 15.108] 
There is no specific information on any of the candidate substances in this subgroup, or on stucturally related 
thiophene derivatives. It may be anticipated that some of the metabolic conversions described above for 
subgroups A-Ia and A-Ib may also apply to this subgroup.  
In addition, the mercapto-group (thiol) in the ring-substituent chain may undergo S-methylation to produce 
the corresponding methyl thioether or sulphide, with further oxidation to the corresponding sulphoxide and 
sulphone. They may also react with glutathione or other endogenous thiol substances to form mixed 
disulphides, which may undergo reduction to thiols, or oxidative desulphuration. Alternatively, they may 
undergo enzymatic oxygenation resulting in the formation of the corresponding sulphinic or sulphonic acid. 
All these metabolites are expected to be excreted in the urine. A more detailed discussion on the metabolism 
of sulphur compounds may be found in an other EFSA-CEF Opinion on other sulphur-containing flavouring 
substances (EFSA, 2011h). 
Additional considerations for the candidate substances in Subgroup A-I 
No information was submitted that would indicate whether side chain oxidation of the alkyl-substituted 
thiophenes or keto-reduction of the acyl-substituted thiophenes could occur. Such reactions may be 
anticipated (e.g. omega or omega-1 oxidations). Similar reactions have been discussed for alkylated furane 
and pyrazines in previous Opinions (EFSA, 2010h; EFSA, 2011h). In addition, the two aldehyde candidate 
substances [FL-no: 15.074 and 15.107] may be expected to be oxidised to the corresponding carboxylic 
                                                     
 
13 
HN
N
S
N
N
*
*
 Structure of Olanzapine; the radioactive carbons are indicated with *.  
FGE.21Rev3
 
 
68 EFSA Journal 2012; 10(2):2457 
acids. Where applicable, conjugation with amino acids (e.g. glycine) or glucuronic acid may also be expected 
to occur (EFSA, 2009f; EFSA, 2010h; EFSA, 2011h).  
Rance (1989) has indicated that unsubstituted thiophene may be subject to S-oxidation and ring substitution. 
It was stated that S-oxides of thiophene are highly reactive. In this review several studies have been quoted 
with C2 substituted thiophene derivatives (in particular the pharmaceuticals tienilic acid, morantel and 
pyrantel) for which it was demonstrated that ring C5 hydroxylation of these substituted thiophenes may 
occur to a considerable extent. In contrast C2, C5 disubstituted thiophenes are less susceptible to ring 
hydroxylation (Rance, 1989). 
Subgroup A-II: Thiazoles  
Candidate substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 15.062, 
15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.080, 15.084, 15.085, 15.089, 15.098, 15.115, 15.116 and 
15.118] 
No specific information was available for any of the candidate substances in this subgroup. 
Non-candidate substances: 
Thiamine hydrochloride [FL-no: 16.027] and 5-(2-hydroxyethyl)-4-methylthiazole [FL-no: 15.014] 
Thiamine (see Figure III.2) is excreted in the urine as unchanged substance but also in the form of 25 - 30 
metabolites, some of which still contain the pyrimidine moiety, while other metabolites are generated as a 
result of molecular cleavage.  
In fish and micro-organisms, breakdown of thiamine is catalysed by two enzymes, namely thiaminase I and 
thiaminase II (Tietz, 1986a; Tanphaichitr, 1976). Based on comparative studies in which rodents were given 
thiamine intravenously or orally, it has been demonstrated that in the gastrointestinal tract thiamine may 
already be split into a pyrimidine and a thiazole derivative, namely 5-(2-hydroxyethyl)-4-methylthiazole, 
which together with its oxidation product (4-methylthiazole-5-acetic acid) and parent thiamine have been 
identified in urine. The fate of the pyrimidine derivative will not be further discussed. The relevance of the 
intraintestinal cleavage may be different among various animal species (Informatics Inc., 1974). 
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Figure III.2. Metabolism of thiamine and 5-(2-hydroxyethyl)-4-methylthiazole 
Chlormethiazole 
The therapeutic agent chlormethiazole (5-(2-chloroethyl)-4-methylthiazole; see Figure III.3), is an alkyl- and 
chloroalkyl-substituted thiazole derivative that is metabolised by C-oxidation of the alkyl- and chloroalkyl-
substituents and by S- and N-oxidation. In male humans, a 1000 mg oral dose of chlormethiazole is 
metabolised via side-chain C-oxidation of the ethyl C1-position to yield 5-(1-hydroxyethyl)-4-
methylthiazole, 5-acetyl-4-methylthiazole, 5-(1-hydroxy-2-chloroethyl)-4-methylthiazole, 4,5-
dimethylthiazole and 4-methylthiazole-5-acetic acid, which is the major C-oxidation urinary metabolite (see 
Figure III.3). Presumably, the 5-methyl derivative is formed via decarboxylation of the 5-acetic acid 
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metabolite. Additionally, oxidation of the methyl group at C4 in 5-(2-hydroxyethyl)-4-methylthiazole yields 
5-(2-hydroxyethyl)-4-thiazolecarboxylic acid lactone. 
Separate ring sulphoxide and ring N-oxide products were not identified, but a combined ring S- and N-oxide 
of a side-chain oxidised metabolite was also eliminated in the 12-hour urine of volunteers. This was the first 
reported example of a sulphoxidation of a thiazole sulphur and simultaneous oxidation of two different 
heteroatoms in the same heteroaromatic ring in vivo (Offen et al., 1985). 
Moore et al. (1975) reported the excretion of urinary metabolites of chlormethiazole after oral administration 
of this anticonvulsant drug (in the form of its unstable chlormethiazole ethanedisulphonate derivative) to 
humans. The substance was given in capsules to three volunteers (sex unknown) in an amount of 768 mg. 
Urinary samples were collected for up to 36 hours post-dosing and processed for the identification and 
quantification of metabolites by GS-MS techniques. Results of urinalysis were compared to results obtained 
with reference substances. After oral administration, about 16 % of the dose could be identified in the 36 
hours urine as 4 substances, parent chlormethiaziole (< 0.01 % of the dose), 5-acetyl-4-methylthiazole, 5-(1-
hydroxyethyl)-4-methylthiazole (free and as unspecified conjugate) and 4-methylthiazole-5-acetic acid (> 75 
% of all metabolites identified). 5-(2-Hydroxyethyl)-4-methylthiazole was only found in trace amounts. In 
addition, a metabolite was tentatively identified as 4-methyl-5-thiazole-acetaldehyde. The authors noted that 
at that time 80 % of the dose was still unaccounted for, which might indicate extensive metabolism of the 
substance in humans (Moore et al., 1975). 
It has also been reported that chlormethiazole undergoes nucleophilic attack at C2, which would ultimately 
result in ring opening. The exact mechanism for the formation of ring opening products has not been well-
described/identified, but the products are nonetheless found in human urine. It was suggested that N-
oxidation followed by glutathione conjugation and subsequent glutathione break-down would yield the 2-
thiomethyl derivative of chlormethiazole, whereas hydroxide ion attack would yield 2,4-pentanedione-3-thiol 
and thiodiacetic acid. The authors suggest that the N-oxidation would make the C2 prone to nucleophilic 
attack (Grupe and Spiteller, 1982; Pal and Spiteller, 1982). According to data from Grupe & Spiteller (1982), 
urinary excretion of thiodiacetic acid may comprise up to about 5 % of the dose of chlormethiazole in 
humans. For the other metabolites (see Figure III.3) no quantitative data were provided. 
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Figure III.3. Metabolism of Chlormethiazole. 
Herbertz et al. (1973) studied the metabolism of (2-14C)-chlormethiazole-ethane disulphonate in isolated 
recycling-perfused rat liver. After 2 hours, 35 % of the system's radioactivity was found in the bile, which 
activity was associated with a polar metabolite, not observed in previous in vivo studies in urine. This 
metabolite was identified as a mixture of N,4-dimethyl-thiazole-5-acetic acid, 2-hydroxy-N,4-dimethyl-
thiazole-5-acetic acid and the glycine conjugate of the latter. Other substances in the perfusate were 
chlormethiazole, 2-hydroxy-4-methyl-5-(2-chloroethyl)thiazole, 4-methyl-5-(2-hydroxyethyl)thiazole, 4-
methylthiazole-5-acetic acid, 2-hydroxy-4-methylthiazole-5-acetic acid and its glycine conjugate (Herbertz 
et al., 1973).  
In vivo, the urine was identified as the primary route of elimination (70 % of the dose within 3 hours in a 
study by Allgen et al., 1963 (cited by Herbertz et al., 1973), with no formation of N-methylated products. 
Hence, it was speculated that in vivo enterohepatic recycling of chlormethiazole-metabolites would occur, in 
particular of the N-methylated substances, which would be de-methylated in the gastro-intestinal tract and 
subsequently be excreted via the kidneys. It was noted that the difference between the observations in vivo 
and the perfused system may have occurred because of the build-up of (secondary) metabolite levels in the 
(closed) perfused system (Herbertz et al., 1973). 
Mizutani et al. (1993) investigated the relationship between the toxicological profile of several thiazole 
derivatives and the toxicity of the ring cleavage products in particular the thioamide metabolites (see Figure 
III.4). The various thiazoles were nephrotoxic in vivo in GSH-depleted mice, which toxicity decreased upon 
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substitution at the ring 4 and 5 carbons. The larger the substituents, the less nephrotoxic the substances 
appeared to be. In addition to being nephrotoxic, some of the thiazoles studied were also hepatotoxic. In the 
ring C4- and C5-substituted derivatives, ring substitution at the 2 position carbon (the one between the S and 
the N atom) markedly reduced the nephrotoxicity, but the hepatotoxicity was maintained, except when the 
substituted was a hydroxyl group (e.g. 2-hydroxy-4-methylthiazole). It was also demonstrated that 
thioformamide was both nephrotoxic and hepatotoxic, but only in GSH-depleted animals. Thioamides from 
ring C2 substituted thiazoles appeared to be only hepatotoxic, both after GSH-depletion and in normal 
animals, although in the normal animals the hepatotoxicity was less pronounced (Mizutani et al., 1993). 
Thus, the toxicity appears to be associated with GSH-depletion, which is a high-dose phenomenon. 
In additional studies, again with mice, administration of another non-flavouring thiazole derivative with 
known hepatotoxic and nephrotoxic properties, 4-t-butyl-2-methylthiazole, at a dose of 312 mg/kg bw by 
gavage, resulted in limited ring C-oxidation. Only 0.25 % of the administered dose was recovered as a ring 
fragmentation product (3,3-dimethyl-2-oxobutanal; an alpha-dicarbonyl metabolite) in the urine within 24 
hours. In addition, a thioamide metabolite (thioacetamide) was found; but this was not quantified. Other 
metabolites were not studied. Based on the structure of the dicarbonyl fragment, it was postulated that the 
4,5-double bond of the thiazole ring undergoes epoxidation followed by hydrolysis to yield 4,5-diol. The diol 
then undergoes hydrolytic cleavage to yield the corresponding carbonyl derivatives and thioacetamide. 
Similar, thiazole ring opening has also been observed with thiabendazole (= 2-(thiazol-4-yl)benzimidazole) 
and with 2-(p-methoxyphenyl)-4-methylthiazole (Mizutani et al., 1994). 
Additional information for candidate substances in Subgroup A-II 
In an extensive review on the metabolism of heterocyclic substances, Rance (1989) indicated that several 
alternative metabolic pathways are available to thiazoles. One involves oxidation of S to form the 
corresponding sulphoxide and sulphone. Electrophilic attack at the ring N (resulting in quaternisation, e.g. N-
methylation) is stated to be even more preferential than S-oxidation. The C2 carbon atom is electron 
deficient and substituents at this position are reactive and subject to nucleophilic displacement, in particular 
if the ring N is quaternised. Another pathway involves electrophilic attack at ring carbons, preferably C5. 
The C5 hydroxythiazoles exist as two tautomeric forms. C5-hydroxylation, however, is quantitatively 
unimportant because thiazoles do not readily undergo electrophilic substitution reactions (Rance, 1989). 
Alkyl- and acyl-substituted thiazole derivatives can be metabolised via side-chain oxidation and ring S- and 
N-oxidation (Dalvie et al., 2002). The major metabolites are readily excreted in the urine either free or as 
glutathione conjugates. In addition, it may be expected that the presence of alkyl- and acyl-substituents at the 
thiazole ring increases the number of metabolic options. It has also been demonstrated that to a very small 
extent ring C-oxidation may be followed by ring cleavage to yield alpha-diketone and thioamide fragments 
(see Figure III.4). The acyl-substituted thiazoles [FL-no: 15.038, 15.039, 15.085 and 15.116] may also be 
expected to undergo keto-reduction, possibly followed by conjugation, similar to acetyl derivatives of furane 
(EFSA, 2011h) and pyrazine (EFSA, 2010h). However, there is very limited information to evaluate the 
extent of metabolism of ring substituent groups, and it is also very difficult, based on the information 
available, to assess how the presence of ring substituents and their positions at the ring might influence the 
metabolism of the ring itself. 
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Subgroup A-III: Benzothiazoles 
2-Methyl-4,5-benzothiazole [FL-no: 15.088] 
No studies are available on the candidate substance in this group. However, there are some data on another 
(more complex) benzothiazole derivative and on benzothiazole [FL-no: 15.016]. The data are presented 
below: 
Benzothiazole is primarily metabolised in guinea pigs by thiazole ring cleavage. A 30 mg/kg bw dose 
administered by intraperitoneal injection is metabolised to free or conjugated forms of o-aminophenyl methyl 
sulphide, o-aminophenyl methyl sulphoxide, and o-aminophenyl methyl sulphone. Small amounts of the N-
hydroxy derivatives of the sulphoxide and sulphone were also detected (Wilson et al., 1991). 
If substitution is present at the 2-position of the thiazole ring, depending on the nature of the substituent, 
hydroxylation of the benzene ring may be observed. In dogs, the calcium channel blocker fostedil (i.e. (4-(2-
benzothiazolyl)phenyl) methylphosphonic acid diethyl ester), a 2-substituted benzothiazole, has been 
claimed to undergo benzene ring hydroxylation mainly at C5, C6 and C7, but experimental details were not 
available (Thomas, 1984). It is not clear if benzene ring hydroxylation would also apply to the one candidate 
substance in this group. 
III.3.2. Non-aromatic candidate substances 
Subgroup B-I: Dihydrothiophenes 
4-Hydroxy-2,5-dimethylthiophen-3(2H)-one [FL-no: 15.077] 
No data were available for the non-aromatic dihydrothiophene candidate substance [FL-no: 15.077]. 
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Rance (1984) has drafted some general rules for the prediction of metabolism of sulphur-heterocycles. One 
of these rules is that with increasing level of ring saturation, the possibilities for S-oxygenation leading to 
sulphoxides and sulphones, will increase due to the lower effect of aromatic stabilisation, which might be 
relevant for the prediction of the metabolism of this candidate flavouring substance (Rance, 1989). 
Subgroups B-II, B-III, B-IV, B-V and B-VI: Thiazoline, Thiazolidine, Dithiazine, Dihydrothiazine and 
Thiadiazine derivatives 
Candidate substances [FL-no: 15.060, 15.086 and 15.119] (thiazolines from subgroup B-II), 
Candidate substances [FL-no: 15.090 and 15.099] (thiazolidines from subgroup B-III), 
Candidate substances [FL-no: 15.042, 15.054, 15.055, 15.057, 15.079 and 15.135] (dithiazines from 
subgroup B-IV), 
Candidate substances [FL-no: 15.114 and 15.133] (dihydrothiazines from subgroup B-V) 
Candidate substance [FL-no: 15.129] (a thiadiazine from subgroup B-VI) 
No specific information was available to evaluate the metabolism of any of the candidate substances 
mentioned in these five subgroups (B-II, B-III, B-IV, B-V and B-VI). 
It may be speculated that the substances in these chemical groups which contain a partially or completely 
reduced thiazole, a dithiazine or a reduced thiazine ring, are metabolised primarily by oxidation of the ring S 
or via N-oxidation, similar to the aromatic thiazole compounds. In addition, metabolism of the ring 
substituents is likely to occur.  
III.4. Summary and Conclusions 
The candidate substances in this FGE are structurally related to 29 flavouring substances evaluated by the 
JECFA in “Safety Evaluations of Groups of Related Flavouring Agents: Sulfur-Containing Heterocyclic 
Compounds”. The candidate and 29 supporting substances in this group were subdivided into 11 subgroups 
based on the nature of the ring (aromatic (clustered in subgroups A-I to A-III) vs. non-aromatic (clustered in 
subgroups B-I to B-VI)), type and number of ring heteroatoms (sulphur or sulphur with nitrogen), and the 
degree of saturation in the non-aromatic rings. 
For the evaluation of the metabolism of the candidate substances in this group, only very limited data were 
available. These were confined to a few references on thiophene, and some thiophene-, thiazole- and 
benzothiazole-derivatives (i.e. only directly relevant for the evaluation of subgroups-A, the aromatic 
candidate substances). Other information was found in several review papers. Virtually no data were found 
on the possible metabolism of the non-aromatic ring structures in the B-subgroups.  
III.4.1. A-subgroups (substances with aromatic ring structures) 
Very few data are available on absorption, distribution and excretion. Some of the studies are related to oral 
exposure and some others to parenteral dosing, and the relevance of the latter may be limited. In mice, a 
thiazolobenzimidazole derivative was rapidly absorbed after oral dosing, S-oxidised, and eliminated from 
plasma. The candidate substance thiophene has been shown to be absorbed rapidly from the gastro-intestinal 
tract and eliminated via urine as metabolites, or via the lungs. Also the thiazole derivative fostedil is 
absorbed from the gastro-intestinal tract (42 - 71 % of the dose), metabolised and eliminated with a plasma 
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half-life of about 6 - 9 hours in dogs. Hence, from the data on absorption and elimination that are available 
for the aromatic candidate substances in this FGE, it may be speculated that most of them will be fairly well 
absorbed and eliminated after biotransformation. Some volatile substances may also be eliminated via the 
lungs. For the non-aromatic candidate substances no information is available. 
From the available metabolism data, it may be anticipated that the sulphur- and nitrogen containing 
heterocyclic and heteroaromatic derivatives participate in metabolic pathways, principally involving side-
chain C-oxidation, oxidation of the ring S and ring N to yield sulphoxide or sulphones and N-oxides, 
respectively. Sulphoxide metabolites may conjugate with glutathione or may undergo dimerisation via a 
Diels-Adler reaction. For substituted thiophenes also epoxidation of the double bonds has been reported, 
which may also be followed by glutathione conjugation and mercapturic acid formation. As far as studied, 
ring C-oxidation may to a very minor extent be accompanied by heterocyclic ring cleavage, which for 
thiazoles could result in the formation of reactive thioamide intermediates. In addition to this cleavage of the 
heterocyclic ring, oxidation of the fused benzene ring has been reported for some structural analogues of the 
one candidate substance 2-methyl-4,5-benzothiazole [FL-no: 15.088] in subgroup A-III (benzothiazoles). 
Additional alkyl and acyl substituents in the thiazole ring may increase the alternative metabolic pathways 
available to thiazole derivatives as was demonstrated for chlormethiazole. Alkyl- and acyl-substituted 
thiazole derivatives are primarily metabolised via side-chain oxidation and ring S- and N-oxidation. The 
major metabolites are readily excreted in the urine either free or as glutathione conjugates. Metabolites of the 
side-chain oxidation pathways may be expected to be conjugated e.g. to glucuronic acid. To a very small 
extent ring C-oxidation may be followed by ring cleavage to yield alpha-diketone and thioamide fragments. 
The acyl-substituted thiazoles [FL-no: 15.038, 15.039, 15.085 and 15.116] may also be expected to undergo 
keto-reduction, possibly followed by conjugation, similar to acyl derivatives of furanes (EFSA, 2011h) and 
pyrazines (EFSA, 2010h).  
Thiophene (subgroup A-Ia) and the ring-substituted thiophenes (subgroups A-Ib and A-Ic) undergo S-
oxidation and glutathione conjugation. Also from some studies with thiazole derivatives, it can be seen that 
their metabolites may react spontaneously with glutathione, and it is likely that they have also reactivity 
towards protein thiols, which may result in toxicity. E.g. for the thiazole-ring cleavage products (thioamide-
intermediates) a relationship with nephrotoxicity and hepatotoxicity has been established, especially after 
GSH depletion, even though this is only a very minor metabolite. 
Limited information was submitted that indicates that side chain oxidation of the alkyl- or acyl-substituted 
thiophenes (subgroups A-Ib and A-Ic) or thiazoles (subgroup A-II) may also occur. Such reactions may be 
anticipated (e.g. omega or omega-1 oxidations). Similar reactions have been discussed for alkylated 
pyrazines (EFSA, 2010h). In addition the two candidate substances with aldehyde groups [FL-no: 15.107 
and 15.074] may be expected to be oxidised to the corresponding carboxylic acids. Where applicable, 
conjugation with amino acids (e.g. glycine) or glucuronic acid may also be expected to occur (EFSA, 2005e; 
EFSA, 2010h; EFSA, 2011h).  
Based on the MSDI exposure estimates (see Table 6.1 of the main text) it seems reasonable to assume that 
saturation of the metabolic pathways for the candidate substances in this FGE is unlikely, given these low 
levels of exposure to the candidate substances from their use as flavouring substances.  
Overall there is insufficient quantitative information to evaluate the extent of metabolism of ring substituent 
groups, and it is also very difficult, based on the data available, to assess how the presence of ring 
substituents and their positions at the ring influences metabolism of the rings itself, for any of the subgroups 
within this FGE. With respect to sulphydryl reactivity in thiophenes (subgroup A-Ic), this property was a 
reason to consider such substances, e.g. FGE.13, as not being metabolised through pathways leading to 
innocuous metabolites. In concordance with this and based on the information presented above, it is 
concluded that for all candidate flavouring substances in A-subgroups of the present FGE, it cannot be 
anticipated that they are metabolised to innocuous metabolites. 
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III.4.2. B-subgroups (substances with non-aromatic ringstructures): 
No specific information was available on the metabolism of the dihydrothiophene-, thiazoline-, thiazolidine-, 
dithiazine-, dihydrothiazine- or thiadiazine-derivatives or of related substances for any of the (non-aromatic) 
substances in the B-subgroups. It may be speculated that the substances in these chemical groups are 
metabolised primarily by oxidation of the ring S which indeed was reported for the thiazolidine derivative 
already mentioned, or, if applicable, via N-oxidation, similar to the aromatic thiazole and thiophene 
compounds. In addition, metabolism of the ring substituents is likely to occur. Due to the lack of metabolism 
data on the substances in the B-subgroups, it cannot be concluded that the candidate flavouring substances in 
the respective B-subgroups will be metabolised to innocuous products. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for two candidate substances of the present flavouring group evaluation and for 17 supporting substances evaluated by 
the JECFA at the 59th meeting. The supporting substances are listed in brackets. 
Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 (mg/kg bw)  Reference  
Thiophene [15.106] 
 
Mouse M Oral 1902 (O’Donoghue, 1979) 
Mouse F Oral > 500 (Eli Lilly and Company, 1992) 
Rat M Oral 1131 (O’Donoghue, 1979) 
Rat M, F Gavage 3120 (Younger, 1964) 
Thiophene-2-carbaldehyde [15.107] 
 
Mouse NR Oral 565 (Sharp, 1979) 
Rat NR Oral 915 (950) (Sharp, 1979) 
(2-Thienyl disulfide [15.008]) Mouse M, F Gavage 400 (Moran et al., 1980) 
(2-Methyl-5-methoxythiazole [15.002]) Rat NR Oral 1250 (Posternak et al., 1975) 
(2,4-Dimethyl-5-vinylthiazole [15.005]) Mouse M, F Oral 400 – 800 (Moran et al., 1980) 
(5-Acetyl-2,4-dimethylthiazole [15.011]) Mouse M, F Gavage 975 (Moran et al., 1980) 
Mouse M, F Gavage M: 610, F: 620 (Shellenberger, 1971d) 
(5-(2-Hydroxyethyl)-4-methylthiazole [15.014]) Mouse M, F Oral 4800 (Calvary and Nelson, 1944) 
(4-Methyl-5-vinylthiazole [15.018]) Mouse M, F Gavage 400 – 800 (Oser, 1970c) 
(2-Propionylthiazole [15.027]) Mouse M, F Gavage 2113 (Moran et al., 1980) 
(4-Methylthiazole [15.035]) Mouse F Gavage 0.36 ml/kg (360 mg/kg, based on an 
assumed specific gravity of 1.0 
g/ml) 
(O’Neal et al., 1978) 
Rat M, F Gavage 930 (Mondino, 1981b) 
(4,5-Dimethylthiazole [15.017]) Rat M, F Gavage 964.9 (Piccirillo et al., 1982a) 
(2-Ethoxythiazole [15.021]) Rat M, F Gavage 910.9 (Piccirillo et al., 1982b) 
(2-Isopropyl-4-methylthiazole [15.026]) Rat M, F Gavage 0.83 ml/kg (832 mg/kg based on a 
specific gravity of 1.003 g/ml) 
(Griffiths and Babish, 1977b) 
(2-Ethyl 4-methylthiazole [15.033]) Rat M, F Oral 540 (Moreno et al., 1981b) 
(Thiamine hydrochloride [16.027]) Rat M Gavage 3710 (Sprince et al., 1974) 
(Benzothiazole [15.016]) Mouse M, F Gavage 900 (Moran et al., 1980) 
Rat M, F Oral 380 (Birch, 1976a) 
Rat M, F Gavage 492 (Younger, 1964) 
Rat M, F Gavage 479 (Reddy and Mayhew, 1992) 
Rat M, F Oral 257 (M), 177 (F) (Loeser, 1982a; Loeser, 1982b) 
(2-(2-Butyl)-4,5-dimethyl-3-thiazoline [15.029]) Mouse M, F Gavage 2827 (Moran et al., 1980) 
(4,5-Dimethyl-2-ethyl-3-thiazoline [15.030]) Mouse M, F Gavage 1265 (Moran et al., 1980) 
(4,5-Dimethyl-2-isobutyl-3-thiazoline [15.032]) Mouse M, F Gavage 3067 (Moran et al., 1980) 
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Subacute / Subchronic toxicity data are available for three candidate substance of the present flavouring group evaluation and for 11 supporting substances 
evaluated by the JECFA at the 59th meeting. No chronic or carcinogenicity studies were available. The supporting substances are listed in brackets.  
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
Thiophene [15.106] Rat;  
M 
5 
Gavage 0, 50, 100, 500, 
1000 mg/kg 
bw/day 
Up to 19 days 100 (O’Donoghue, 1979) Inadequately reported study of short duration.  
Rat; 
M/F 
13 
Gavage 0, 25, 100, 400 
mg/kg bw/day 
42 25 (Nagao, 2006) Only a translated summary report available. 
2-Pentylthiophene [15.096] Rat; 
M/F 
5 
Gavage 0, 15, 150, 500 
mg/kg bw/day 
28 15 (Dhinsa et al., 2006)  
Rat; 
M/F 
5 
Gavage 0, 3 mg/kg 
bw/day 
28 3 (Marr and Watson, 
2007) 
 
Thiophene-2-carbaldehyde [15.107] Rat;  
sex not reported 
5 
Diet  0, 0.1, and 1.0 % 
in diet equal to 
0, 95 and 840 
mg/kg bw/day 
11 days 95 (Sharp, 1979) Reduced food consumption and reduced absolute kidney weight. 
Inadequately reported study of short duration. 
(5-Methyl-2-thiophenecarbaldehyde 
[15.004]) 
Rat; 
M, F 
5/sex/group 
Diet  10 mg/kg 
bw/day 
14 days 10 (Gill and Van Miller, 
1987b) 
One dose level, GLP study, comprehensively reported, but no 
haematology or clinical chemistry carried out, only a limited number of 
organs examinaed at autopsy and only liver and kidney examined 
histopathologically. Short duration, limited study design. 
(3-Acetyl-2,5-dimethylthiophene 
[15.024]) 
Rat;  
M, F 
5/sex/group 
Diet  10 mg/kg 
bw/day 
14 days 10 (Gill and Van Miller, 
1987b) 
One dose level, GLP study, described as a dietary Minimum Toxicity 
Screen (MTS), comprehensively reported, but no haelatology or clinical 
chemistry carried out, only a limited number of organs examinaed at 
autopsy and only liver and kidney examined histopathologically. Minor 
body weight changes in both sexes and organ weight changes in males 
only. Short duration, limited study design. 
(2-Thienyl disulfide [15.008]) Rat;  
M, F 
15/sex 
Diet  0.29 mg/kg bw/ 
day 
90 days 0.29 (Morgareidge and Oser, 
1970g) 
Study carried out at a one low dose level. Standard toxicological 
parameters were monitored (body weight, food consumption, 
haematology, urinalysis, histopathology). Parameters assessed were 
reasonably comprehensive. Study considered valid. 
(5-Acetyl-2,4-dimethylthiazole [15.011]) Rat;  
M, F 
23/sex 
Diet approx. 25 
mg/kg bw/day. 
90 days M: 25.2 
F:24.4 
(Shellenberger, 1971d) Old study carried out at a one dose level. Standard toxicological 
parameters were monitored (body weight, food consumption, 
haematology, urinalysis, histopathology). Parameters assessed were 
reasonably comprehensive. Study considered valid. 
(2-Acetylthiazole [15.020]) Rat; M 
5 
Diet  5000 and 10,000 
mg/kg in diet 
equivalent to 
250 and 500 
mg/kg bw/day 
28 days < 250 (Wheldon et al., 1970) Preliminary dose-range finding study for the 90-day study described 
below, very limited experimental details provided. 
Rat; M 
10 
Diet  0. 100, 1000, 
10,000 mg/kg in 
diet equivalent 
90 days 50 (Wheldon et al., 1970) Study considered to be of limited validity, since no clinical chemistry 
was undertaken, limited number of organs weighed, number of organs 
taken for histopathology was limited, and histopathological review 
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Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
to 0.5, 50, 500 
mg/kg bw/day 
restricted to 5 animals/sex/group.  
(2-Methyl-5-methoxythiazole [15.002]) Rat; 
M, F 
10-16/sex 
Diet  approx. 9 mg/kg 
bw/day 
90 days M: 8.83 
F: 8.63 
(Posternak et al., 1975) Toxicity data reported as part of a summary publication on a large 
number of flavouring substances. Body weight, food utilisation, 
haematological and histopathology examination undertaken, clinical 
chemistry restricted to blood urea nitrogen, organ weight changes 
restricted to liver and kidney. Due to reporting limitations data quality 
could not be assessed.  
(2,4-Dimethyl-5-vinylthiazole [15.005]) Rat; M, F 
10-16/sex 
Diet  approx. 1 mg/kg 
bw/day 
90 days M: 0.92 
F: 1.0 
(Posternak et al., 1969) Toxicity data reported as part of a summary publication on a large 
number of flavouring substances. Body weight, food utilisation, 
haematological and histopathology examination undertaken, clinical 
chemistry restricted to blood urea nitrogen, organ weight changes 
restricted to liver and kidney. Due to reporting limitations data quality 
could not be assessed.  
(Benzothiazole [15.016]) Rat;  
M, F 
15/sex  
Oral 5.1 mg/kg bw/ 
day 
90 days 5.1 (Morgareidge, 1971c) 
Body weight, food utilisation, haematology and limited clinical 
chemistry parameters were evaluated, and a range of tissues was 
examined microscopically. No treatment-related effects were seen. Only 
the histopathological report was available for the current evaluation. 
The study is considered valid. 
2-(2-Butyl)-4,5-dimethyl-3-thiazoline 
[15.029]) 
Rat; 
M, F 
15/sex  
Oral 1.21(M) /1.26 
(F) mg/kg bw/ 
day 
90 days M: 1.21 
F: 1.26 
(Babish and Re, 1978) Old study carried out at a one dose level. Standard toxicological 
parameters were monitored (body weight, food consumption, 
haematology, urinalysis, histopathology). Study considered valid. 
(2- Isobutyl-4,6-dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-2,6-
dimethyldihydro-1,3,5-dithiazine 
(mixture)) 
Rat,  
M, F 
5/sex 
Oral 10 mg/kg 
bw/day 
14 days M: 11.5 
F: 11.1 
(Rush, 1989a) One dose level study of short duration, no haematological or clinical 
chemistry parametes were examined and histopathological examinations 
were restricted to liver and kidney.  
(2- Isopropyl-4, 6-dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-2,6-
dimethyldihydro-1,3,5-dithiazine 
(mixture)) 
Rat,  
M, F 
5/sex 
Oral 10 mg/kg 
bw/day 
14 days M: 11.8 
F: 11.1 
(Rush, 1989b) One dose level study of short duration, no haematological or clinical 
chemistry parametes were examined and histopathological examinations 
were restricted to liver and kidney.  
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Developmental and reproductive toxicity data are available for one candidate substance of the present Flavouring Group Evaluation and for none of the 
supporting substances evaluated by the JECFA at the 59th meeting. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no] Species/ Sex 
No./ group 
Route Dose 
Levels 
Duration NOAEL (mg/kg bw/day), Including 
information of possible maternel 
toxicity 
Reference Comments 
Thiopene [15.106] Rats/M, F 
13 
 
Gavage 0, 25, 100, 400 
mg/kg bw/day 
42 days M: 400 mg/kg bw 
F: 25 mg/kg bw 
(Nagao, 2006) Only a translated summary report available. 
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In vitro mutagenicity/genotoxicity data are available for 12 candidate substances of the present flavouring group evaluation from chemical group 29 or 30 and 
for four supporting substances evaluated by the JECFA at the 59th meeting and four related supporting substances. Supporting substances are listed in 
brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test System Test Object  Concentration Result  Reference  Comments 
Subgroup A-Ia 
Thiophene [15.106] Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
3 µmol/plate (all strains) 
(252 µg/plate) 
Negative (±S9) (Florin et al., 1980) Published non-GLP study. Qualitative screening in a spot-
test with three strains, quantitative study (4 doses, 0.03, 0.3, 
3, 30 µmol/plate) with TA 100 only. Limited report of 
experimental details and results. Insufficient quality, study 
not considered adequate for the evaluation of mutagenic 
activity. 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA97;TA98; TA100; 
TA1535; TA1537 
Up to 10,000 µg/plate  Negative (±S9)1 (Zeiger et al., 1987) Non-GLP study roughly in accordance with OECD 
guideline 471. The study is considered valid. 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.01-1.2 mmol/plate  
(100,968 µg/plate) 
Negative (±S9) (Aeschbacher et al., 1989) Greatest effects are quantified by ”mutation factor,” no 
numbers are given for negative results. Limited quality 
(only 3 strains used), but otherwise acceptable study.  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(8414 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
Ames assay S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
0, 78.1, 156, 313, 625, 
1250 µg/plate 
Negative (±S9) (Shibuya, 2006) Valid study according to OECD Test Guidelines and 
Guidelines for screening mutagenicity testing of chemicals 
(Japan), provided as a translation of the original report in 
Japanese.  E. coli WP2 uvrA 0, 78.1, 156, 313, 625, 
1250,2500, 5000 
µg/plate 
Negative (±S9) 
Chromosomal 
Abberation 
Chinese hamster lung 
cells 
0, 210, 420, 840 µg/ml Negative (±S9) (Tanaka, 2006) Valid study according to Guidelines for screening 
mutagenicity testing of chemicals (Japan), provided as a 
translation of the original report in Japanese. 
Subgroup A-Ib 
2-Methylthiophene [15.091] Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.00001- 1.0 mmol/plate  
(98,170 µg/plate) 
Negative (±S9) (Aeschbacher et al., 1989) Greatest effects are quantified by ”mutation factor,” no 
numbers are given for negative results. Limited quality 
(only 3 strains used), but otherwise acceptable study.  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9817 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
3-Methylthiophene [15.092] Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.01-1.0 mmol/plate  
(98,170 µg/plate) 
Negative (±S9) (Aeschbacher et al., 1989) Greatest effects are quantified by ”mutation factor,” no 
numbers are given for negative results. Limited quality 
(only 3 strains used), but otherwise acceptable study.  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9817 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
2,5-Dimethylthiophene [15.064] Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11,219 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test System Test Object  Concentration Result  Reference  Comments 
2-Acetylthiophene [15.040] Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12,618 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
 SOS Chromotest E. coli NR  Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of 
genotoxic potential. 
2-Acetyl-3-Methylthiophene 
[15.037] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of 
genotoxic potential.  
Thiophene-2-carbaldehyde 
[15.107] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of 
genotoxic potential. 
5-Ethylthiophene-2-
carbaldehyde [15.074] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of 
genotoxic potential. 
(5-Methyl-2-
thiophenecarbaldehyde 
[15.004]) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12,618 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
Subgroup A-II  
2,4-Dimethylthiazole [15.062] Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA100 
9.3 and 94 mmol/l top 
agar 
(10,639 µg/ml) 
Negative (-S9) (Voogd et al., 1983) Insufficient quality (one test strain as well as without 
metabolic activation only).  
(4,5-Dimethylthiazole [15.017]) Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11,318 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
(4-Methylthiazole [15.035]) Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9916 µg/plate) 
Negative (±S9) (Lee et al., 1994a) Only two strains used but otherwise acceptable study. 
Subgroup A-III  
2-Methyl-4,5-benzothiazole 
[15.088] 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100; 
TA102; TA1535; 
TA1537 
100-10,000 µg/plate  Negative (±S9)1 (Longfellow, 1998a) Summary report of NCI-short-term test program, results not 
given in detail. 
(Benzothiazole [15.016]) Ames assay S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
Up to 5000 µg/plate   Negative (±S9) (Bayer, 1991) Summary in IUCLID data set only. According to this 
summary, the assay was in compliance with GLP; 
accordance with OECD guideline 471 not stated. 
Mouse lymphoma 
assay 
Mouse 
L5178Y tk+/- cells 
10-250 µg/ml  Negative (±S9) (Longfellow, 1997) Summary report of NCI-short-term test program, results not 
given in detail. 
Subgroup B-III 
2-Propylthiazolidine [15.099] Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 and 10 µg/ml: positive in 
TA100 (±S9); 
100 µg/ml: positive in 
TA98 and TA100.(±S9) 
(Mihara and Shibamoto, 1980) The results were stated to be positive, however, the 
magnitude and a positive dose effect relationship could not 
be assessed (no numbers are given). 
2-Methylthiazolidine [15.090] Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 and 10 µg/ml: positive in 
TA100; (±S9) 
100 µg/ml: positive in 
TA98 and TA100 (±S9) 
(Mihara and Shibamoto, 1980) The results were stated to be positive, however, the 
magnitude and a positive dose effect relationship could not 
be assessed (no numbers are given). 
(2-Ethylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 µg/ml: positive in TA100 
(±S9) and TA98 (-S9); 
10 µg/ml: positive in 
(Mihara and Shibamoto, 1980) The results were stated to be positive, however, the 
magnitude and a positive dose effect relationship could not 
be assessed (no numbers are given). 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name  Test System Test Object  Concentration Result  Reference  Comments 
TA100 (±S9);  
100 µg/ml: positive TA98 
and TA100. 
(±S9) 
(2-Isopropylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 and 10 µg/ml: positive in 
TA100 (±S9);  
100 µg/ml: positive in 
TA100 (±S9) and TA98 (-
S9) 
(Mihara and Shibamoto, 1980) The results were stated to be positive, however, the 
magnitude and a positive dose effect relationship could not 
be assessed (no numbers are given). 
(2-Butylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 µg/ml: positive in TA100 
(+S9);  
10 µg/ml: positive in 
TA100 (±S9);  
100 µg/ml: positive in 
TA100 (±S9) and TA98 (-
S9) 
(Mihara and Shibamoto, 1980) The results were stated to be positive, however, the 
magnitude and a positive dose effect relationship could not 
be assessed (no numbers are given). 
(2-Isobutylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 µg/ml: positive in TA98 
and TA100 (+S9);  
10 µg/ml: positive in TA98 
and TA100 (±S9);  
100 µg/ml: positive in 
TA98 and TA100 (±S9)  
(Mihara and Shibamoto, 1980) The results were stated to be positive, however, the 
magnitude and a positive dose effect relationship could not 
be assessed (no numbers are given). 
NR Not Reported. 
1 With and without rat and hamster S9 metabolic activation.  
FGE.21Rev3
 
 
83 EFSA Journal 2012; 10(2):2457 
TABLE IV.5: GENOTOXICITY (IN VIVO) 
No in vivo mutagenicity/genotoxicity data are available neither for the candidate substance of the present flavouring group evaluation nor for the supporting 
substances evaluated by the JECFA at the 59th meeting.  
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
GLP  Good Laboratory Practice 
GSH  Glutathione 
FLAVIS (FL) Flavour Information System (database) 
HPLC  High-performance liquid chromatography 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IP   Intraparenteral 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
MTS  Minimum Toxicity Screen 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
NMR  Nuclear magnetic resonance 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
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NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
SC  Structural class 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
